Anopheles salivary antigens as serological biomarkers of 1

vector exposure and malaria transmission: A systematic 2

review with multilevel modelling 3

- Ellen A Kearney^{1,2}, Paul A Agius^{1,2,3}, Victor Chaumeau^{4,5}, Julia C Cutts^{1,6}, Julie A Simpson², Freya JI 4
- 5 Fowkes1,2,3*
- 6 ¹ The McFarlane Burnet Institute of Medical Research and Public Health, Melbourne, Victoria,
- 7 Australia
- 8 ² Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The
- 9 University of Melbourne, Melbourne, Victoria, Australia
- ³ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, 10
- 11 Australia
- 12 ⁴ Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical
- 13 Medicine, Mahidol University, Mae Sot, Thailand
- ⁵ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of 14
- Oxford, Oxford, United Kingdom 15
- 16 ⁶ Department of Medicine at the Doherty Institute, The University of Melbourne, Melbourne, Victoria,
- 17 Australia
- 18 * Corresponding author:
- 19 Email: freya.fowkes@burnet.edu.au (FJIF)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Background: Entomological surveillance for malaria is inherently resource-intensive and produces crude population-level measures of vector exposure which are insensitive in low-transmission settings. Antibodies against Anopheles salivary proteins measured at the individual-level may serve as proxy biomarkers for vector exposure and malaria transmission, but their relationship is yet to be quantified. Methods: A systematic review of studies measuring antibodies against Anopheles salivary antigens (PROSPERO: CRD42020185449). Multilevel modelling estimated associations seroprevalence with Anopheles human biting rate (HBR) and malaria transmission measures. Results: From 3981 studies identified in literature searches, 42 studies across 16 countries were included contributing 393 meta-observations of anti-Anopheles salivary antibodies determined in 42,764 samples. A positive non-linear association between HBR and seroprevalence was found; overall a 50% increase in HBR was associated with a 13% increase in odds of seropositivity (OR: 1.13, 95% CI: 1.06-1.20, p<0.001). The association between HBR and Anopheles salivary antibodies was strongest with concordant, rather than discordant Anopheles species. Seroprevalence was also significantly positively associated with established epidemiological measures of malaria transmission: entomological inoculation rate, *Plasmodium* spp. prevalence, and malarial endemicity class. Conclusions: Anopheles salivary antibody biomarkers can serve as a proxy measure for HBR and malaria transmission, and could monitor vectorial capacity and malaria receptivity of a population to sustain malaria transmission. Validation of Anopheles species-specific biomarkers are important given the global heterogeneity in the distribution of Anopheles species. Salivary biomarkers have the potential to transform surveillance by replacing impractical, inaccurate entomological investigations, especially in areas progressing towards malaria elimination.

Funding: Australian National Health and Medical Research Council, Wellcome Trust.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Sensitive and accurate tools to measure and monitor changes in malaria transmission are essential to track progress towards malaria control and elimination goals. Currently, the gold standard measurement of malaria transmission intensity is the entomological inoculation rate (EIR), a population-measure defined as the number of infective Anopheles mosquito bites a person receives per unit of time. EIR is calculated as the human biting rate (HBR; measured at the population-level by entomological vectorsampling methodologies (gold standard: human landing catch)) multiplied by the sporozoite index (proportion of captured *Anopheles* with sporozoites present in their salivary glands). However, estimation of EIR and HBR via entomological investigations are inherently labour and resource intensive, requiring trained collectors, specialised laboratories and skilled entomologists. Furthermore, these approaches provide a crude population-level measure of total vector exposure at a particular time and location, precluding investigation of heterogeneity and natural transmission dynamics of individuallevel vector-human interactions [1]. For example, indoor human landing catches provide poor estimates of outdoor biting and thus total vector exposure [2]. The sensitivity of EIR is further compromised in low transmission settings where the number of *Plasmodium*-infected specimens detected is low and often zero. Evaluation of the human antibody response to Anopheles spp. salivary proteins has the potential to be a logistically practical approach to estimate levels of exposure to vector bites at an individual-level. Several Anopheles salivary proteins have been shown to be immunogenic in individuals naturally exposed to the bites of Anopheles vectors and have been investigated as serological biomarkers to measure Anopheles exposure [3-11], malaria transmission [12-14] and as an outcome for vector control intervention studies [4-6, 14, 15]. However, a major short-coming of the literature is that studies are largely descriptive and do not quantify the association between entomological and malariometric measures and anti-Anopheles salivary antibody responses. We undertook a systematic review with multilevel modelling, to quantify the association between HBR, EIR, and other markers of malaria transmission, with anti-Anopheles salivary antibody responses and to understand how these associations vary according to transmission setting and dominant *Anopheles* vectors. This knowledge is pertinent to

advance the use of salivary antibody biomarkers as a vector and malaria transmission sero-surveillance

72 tool.

71

73

74

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

Methodology

Search strategy and selection criteria

75 We performed a systematic review with multilevel modelling according to the MOOSE and PRISMA

guidelines [16, 17] (Reporting Standards Document). Five databases were searched for published

studies investigating antibodies to Anopheles salivary antigens as a biomarker for mosquito exposure

or malaria transmission published before 30th of June 2020. The protocol (Supplementary File 1) was

registered with PROSPERO (CRD42020185449).

The primary criteria for inclusion in this systematic review was the reporting of estimates of

seroprevalence or total levels of Immunoglobulin (Ig) in human sera against Anopheles salivary

antigens. We considered for inclusion: cross-sectional, cohort, intervention and case-control studies of

individuals or populations living in all geographies with natural exposure to Anopheles mosquitoes.

Studies that were solely performed in participants not representative of the wider naturally exposed

population (i.e. mosquito allergic patients, soldiers, returned travellers) were excluded.

Measures

Outcomes

The primary outcome of our systematic review was antibodies (seroprevalence or levels, including all

Ig isotypes and subclasses) against any Anopheles salivary antigens (full-length recombinant proteins,

peptides and crude salivary extract). As measurement of antibody levels does not produce a common

metric between studies only values of seroprevalence could be included in multilevel modelling

analyses. Therefore, to maximise data, authors of studies that reported only antibody levels were

contacted and asked to classify their participants as 'responders' or 'non-responders' according to

seropositivity (antibody level relative to unexposed sera). Studies that provided antibody levels or

categorised seropositivity based upon arbitrary cut offs are included in narrative terms only.

Exposures

The primary exposures of interest were the entomological metrics HBR (average number of bites received per person per night) and EIR (infectious bites received per person per year). Secondary exposures included study-reported prevalence of *Plasmodium* spp. infection (confirmed by either microscopy, rapid diagnostic test, or polymerase chain reaction (PCR)) and seroprevalence of antimalarial antibodies against pre-erythrocytic and blood-stage *Plasmodium* spp. antigens. Where exposure estimates were not provided, we attempted to source data from other publications by the authors, or using the site geolocation and year to obtain estimates of EIR from the Pangaea dataset [18], *P. falciparum* rates in 2-10 year olds (*Pf*PR₂₋₁₀) and dominant vector species (DVS) from the Malaria Atlas Project (MAP) [19]. Malarial endemicity classes were derived by applying established endemicity cut-offs to *Pf*PR₂₋₁₀ estimates [20]. For the purposes of the modelling analyses we defined DVS as where *An. gambiae sensu lato* (*s.l.*) was the only DVS, where *An. gambiae s.l.*, was present with additional DVS, or where *An. gambiae s.l.* was absent. Studies of salivary antigens where exposure variables could not be sourced and data could not be extracted were excluded.

Statistical analysis

Where seroprevalence estimates of antibodies against the same salivary antigen and exposure of interest were reported in more than one study, generalised multilevel (mixed-effects, logistic) modelling was used to quantify associations between the exposures of interest and salivary antibody seroprevalence measurements [21]. Random intercepts for study and country were included to account for nested dependencies induced from multiple meta-observations (level one) from the same study (level two) and multiple studies from the same country (level three). Additionally, a random slope for the entomological and malariometric exposure parameters was included to model study-specific heterogeneity in the effect of the exposure of interest (HBR/EIR/malaria prevalence/antimalarial antibody seroprevalence). The associations between the various exposures and the different salivary antigens were analysed separately,

however estimates of IgG seroprevalence against the recombinant full-length protein (gSG6) and synthetic peptide (gSG6-P1, the one peptide determined in all studies utilising peptides) form of the gSG6 antigen were analysed together. Potential effect modification of the associations between exposures and anti-Anopheles salivary antibody responses were explored. In analyses quantifying the associations between HBR, as well as EIR, and seropositivity, we included an interaction term with DVS and for vector collection method (human landing catch or other indirect measures e.g. light traps, spray catches, etc.). For the association between Plasmodium spp. prevalence and seropositivity, interaction terms with malaria detection methodology (light microscopy or PCR) and malarial species (P. falciparum only, or P. falciparum and P. vivax) were estimated. The natural log of the exposure measures (HBR, EIR, malaria prevalence and antimalarial antibody seroprevalence) were estimated in modelling to account for their non-linear associations with seroprevalence. Intraclass correlation coefficients (ICCs) were estimated for country- and studyspecific heterogeneity using estimated model variance components. All statistical analyses were performed using STATA v15.1. Risk of bias in individual studies Risk of bias was assessed by one reviewer using the Risk of Bias in Prevalence Studies tool [22]. The risk of bias pertains to the reported seroprevalence estimates of anti-Anopheles salivary antibodies included in the multilevel modelling.

Results

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141


142

143

144

Literature searches identified 158 potentially relevant studies, of which 42 studies were included in the systematic review (Figure 1) and are described in Table 1. Briefly, studies were performed in 16 countries mostly in hypo or mesoendemic areas of Africa where *An. gambiae s.l.* is a dominant vector (n=32), with a minority performed in South America (n=4), Asia (n=4), and the Pacific (n=2) where *An. gambiae s.l.* is not found. In total, our review included 393 meta-observations of anti-*Anopheles*

salivary antibodies determined from antibody measurements in a total of 42,764 sera samples. The salivary antigen most commonly assessed was *An. gambiae* Salivary Gland 6 (gSG6), as a full-length protein (n=8) and synthetic peptide (*An. gambiae* Salivary Gland 6 Peptide 1; gSG6-P1; n=24). Additional salivary antigens assessed included *An. gambiae* gSG6-P2 (n=3), recombinant cE5 (n=2), g-5'nuc (n=1), and recombinant *An. funestus* fSG6 (n=2) and f-5'nuc (n=1). Seven studies measured antibodies to whole salivary gland extracts from *An. gambiae* (n=4), *An. darlingi* (n=2), *An. albimanus* (n=1), and *An. dirus* (n=1), while one study assessed antibodies against synthetic peptides of *An. albimanus* (Table 1). All studies investigated total IgG and only five determined an additional isotype or subclass [7, 23-26]. The paucity of studies investigating these latter-mentioned antibody types and *Anopheles* salivary biomarkers precluded extensive multilevel analyses; instead, we present their associations in narrative terms in Supplementary File 5. Analyses reported below focus on quantifying the relationships between HBR, EIR and markers of malaria transmission with total IgG to *An. gambiae* gSG6. The distributions of exposure estimates were: HBR (median: 3.1 bites per person per night, IQR: 0.9-12.1; range: 0-121.4), EIR (median: 7.3 infectious bites received per person per year, IQR: 0-36.4; range: 0-585.6), and *Plasmodium* spp. prevalence (median: 9.1%; IQR: 4-22%; range: 0-94.6%).



162 Figure 1. Flow diagram of study identification. Excluded studies are detailed in Figure 1 – 163 Supplement 1.

Table 1: Key descriptive information from included studies

Study year	Country	Malarial endemicity class	Dominant malaria vector species	Study design	No. participants (samples)	Meta-N	Vector and malariometric variables	Salivary antibody outcomes (Seroprevalence[%];[L]evels)
Africa								
Brosseau 2012 [27]	Angola	Hypoendemic; Mesoendemic	An. funestus	Cross-sectional [‡]	(1584)	6	Plas+LM; PfPR	gSGE IgG [L]
Drame 2010 [5]	Angola	Hypoendemic	An. gambiae s.l.	Cohort	105 (1470)	12	HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Drame 2010 [6]	Angola	Hypoendemic	An. gambiae s.l.	Cohort	109 (1279)	12	HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR	gSGE IgG [L]
Marie 2015 [28]	Angola	Hypoendemic	An. gambiae s.l.	Cohort	71 (852)	12	HBR; <i>Pf</i> PR	gcE5 IgG [L]
Drame 2015 [7]	Benin	Hyperendemic	An. gambiae s.l.; An. funestus	Cohort [‡]	133 (532)	4	HBR; <i>Pf</i> PR	gSG6-P1 IgG & IgM [%;L]
Rizzo 2011 [9]	Burkina Faso	Hyperendemic*	An. gambiae s.l.	Repeated cross- sectional	(2066)	14	HBR; EIR; Plas+ ^{LM§}	gSG6 IgG [%;L]
Rizzo 2011 [8]	Burkina Faso	Hyperendemic*	An. gambiae s.l.	Repeated cross- sectional	335 (335)	3	HBR	fSG6 IgG [%;L]
Rizzo 2014 [24]	Burkina Faso	Hyperendemic*	An. gambiae s.l.	Repeated cross- sectional	(359)	3	HBR	gcE5 IgG [%;L]; IgG1 & IgG4 [L]
Rizzo 2014 [25]	Burkina Faso	Hyperendemic*	An. gambiae s.l.	Repeated cross- sectional	270 (270)	6	HBR	gSG6 IgG1 & IgG4 [L]
Soma 2018 [29]	Burkina Faso	Mesoendemic	An. gambiae s.l.	Cross-sectional	1728 (273)	6	HBR; EIR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Koffi 2015 [30]	Cote d'Ivoire	Hypoendemic; Mesoendemic	An. gambiae s.l.; An. funestus†	Cross-sectional	94 (94)	3	Plas+ ^{LM} ; Pf-IgG; PfPR	gSG6-P1 IgG [%;L]
Koffi 2017 [31]	Cote d'Ivoire	Hypoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional	234 (234)	5	Pf-IgG; PfPR	gSG6-P1 IgG [%;L]
Traoré 2018 [32]	Cote d'Ivoire	Hypoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional [‡]	89 (178)	4	HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR	gSG6-P1 IgG [L]
Traoré 2019 [33]	Cote d'Ivoire	Hypoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional [‡]	(442)	6	HBR; <i>Plas</i> + ^{LM} ; <i>Pf</i> PR	gSG6-P1 IgG [%;L]

Sadia-Kacou 2019 [34]	Cote d'Ivoire	Mesoendemic	An. gambiae s.l.	Repeated cross- sectional [‡]	775 (775)	8	<i>Pf</i> PR	gSG6-P1 IgG [L]
Badu 2015 [35]	Ghana	Mesoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional [‡]	295 (885)	3	Plas+ ^{LM} ; Pf-IgG; PfPR	gSG6-P1 IgG [%;L]
Badu 2012 [3]	Kenya	Hypoendemic; Mesoendemic	An. gambiae s.l.	Repeated cross- sectional	(1366)	5	EIR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Sagna 2013[36]	Senegal	Hypoendemic; Mesoendemic	An. gambiae s.l.	Cohort [‡]	265 (1325)	25	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Drame 2012 [11]	Senegal	Hypoendemic	An. gambiae s.l.	Cross-sectional	1010 (1010)	16	HBR; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Poinsignon 2010 [37]	Senegal	Hypoendemic	An. funestus	Cohort [‡]	87 (261)	3	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSG6-P1 IgG [L]
Sarr 2012 [38]	Senegal	Hypoendemic; Mesoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional [‡]	(401)	4	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> -IgG; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Lawaly 2012 [23]	Senegal	Mesoendemic	An. gambiae s.l.; An. funestus†	Cohort	387 (711)	4	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSGE IgG, IgG4 & IgE [L]
Ali 2012 [39]	Senegal	Hypoendemic;* Mesoendemic;* Hyperendemic*	An. gambiae s.l.; An. funestus; An. pharoensis	Cross-sectional	(134)	3	HBR; EIR	gSG6 IgG [%;L] fSG6 IgG [%;L]; f5'nuc IgG [%;L]; g5'nuc IgG [%;L]
Ambrosino 2010 [40]	Senegal	Hypoendemic;* Mesoendemic;* Hyperendemic*	An. gambiae s.l.; An. funestus; An. pharoensis	Cross-sectional	(123)	3	EIR; Pf-IgG	gSG6-P1 IgG [%]; gSG6-P2 IgG [%]
Perraut 2017 [41]	Senegal	Hypoendemic; Mesoendemic	An. gambiae s.l.; An. funestus	Repeated cross- sectional	(798)	4	EIR; <i>Plas</i> + ^{LM} ; <i>Plas</i> + ^{PCR} ; <i>Pf</i> -IgG; <i>Pf</i> PR	gSG6-P1 IgG [%]
Poinsignon 2008 [42]	Senegal	Mesoendemic	An. gambiae s.l.	Cross-sectional [‡]	241 (241)	3	HBR; <i>Pf</i> PR	gSG6-P1 IgG [L]; gSG6-P2 IgG [L]
Poinsignon 2009 [43]	Senegal	Mesoendemic	An. gambiae s.l.	Repeated cross- sectional [‡]	61 (122)	2	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSG6-P1 IgG [L]
Remoue 2006 [44]	Senegal	Mesoendemic	An. gambiae s.l.	Cross-sectional [‡]	448 (448)	4	HBR; <i>Plas</i> + ^{LM§} ; <i>Pf</i> PR	gSGE IgG [%;L]
Sagna 2019 [45]	Senegal	Hypoendemic	An. gambiae s.l.	Cross-sectional [‡]	809 (809)	4	<i>Pf</i> PR	gSG6-P1 IgG [L]

Stone 2012 [10]	Tanzania	Mesoendemic; Hyperendemic	An. gambiae s.l.	Cross-sectional [‡]	636 (636)	16	HBR; <i>Pf</i> -IgG; <i>Pf</i> PR	gSG6 IgG [%;L]
Yman 2016 [46]	Tanzania	Mesoendemic; Holoendemic*	An. gambiae s.l.; An. funestus	Repeated cross- sectional [‡]	668 (668)	16	Pf-IgG; PfPR	gSG6 IgG [%]
Proietti 2013 [47]	Uganda	Mesoendemic	An. gambiae s.l.; An. funestus†	Repeated cross- sectional	509 (509)	3	Pf-IgG; PfPR	gSG6 IgG [%]
Americas								
Andrade 2009 [48]	Brazil	Eliminating; Hypoendemic	An. darlingi	Cross-sectional	204 (204)	3	Plas+ ^{LM¶} ; Plas+ ^{PCR¶} ; PfPR	d SGE IgG [L $^{\parallel}$]
Londono- Renteria 2015 [12]	Colombia		An. albimanus	Cross-sectional	42 (42)	2	Plas+PCR¶	g SG6-P1 IgG [L $^{\parallel}$]
Londono- Renteria 2020 [49]	Colombia	Eliminating	An. albimanus	Cross-sectional	337 (337)	2	Plas+PCR; PfPR	<i>a</i> PEROX-P1, P2 & P3 IgG [L]; <i>a</i> TRANS-P1 & P2 IgG [L]
Montiel 2020 [50]	Colombia	Eliminating	An. albimanus	Case-control	113 (113)	2	Plas+LM; Plas+PCR¶; PfPR	gSG6-P1 IgG [L]; dSGE IgG [L]; aSTECLA SGE IgG [L]; aCartagena SGE IgG [L]
Asia								
Kerkhof 2016 [51]	Cambodia	Hypoendemic	An. dirus	Cross-sectional	(8438)	113	Plas+PCR; Pf-IgG; Pv-IgG; PfPR	gSG6-P1 IgG [%;L]; gSG6-P2 IgG [%;L]
Charlwood 2017 [52]	Cambodia	Eliminating	An. dirus	Repeated cross- sectional	454 (1180)	6	HBR; Pf-IgG; PfPR	gSG6 IgG [L]
Ya-Umphan 2017 [13]	Myanmar	Eliminating	An. minimus; An. maculatus	Repeated cross- sectional	2602 (9425)	28	HBR; EIR; Plas+ ^{PCR} ; Pf-IgG; PfPR	gSG6-P1 IgG [%;L]
Waitayakul 2006 [26]	Thailand		An. dirus	Case-control	139 (139)	3	Plas+ ^{LM}	dir SGE IgG & IgM [L $^{\parallel}$]
Pacific								
Pollard 2019 [53]	Solomon Islands	Eliminating; Hypoendemic	An. farauti	Repeated cross- sectional	686 (791)	9	HBR; EIR; <i>Pf</i> PR	gSG6-P1 IgG [%;L]
Idris 2017 [15]	Vanuatu	Eliminating; Hypoendemic; Mesoendemic	An. farauti	Repeated cross- sectional	905 (905)	3	Plas+ ^{LM} ; Pf-IgG; Pv-IgG; PfPR	gSG6 IgG [%;L]

Data are given as: study, year of publication, country, malarial endemicity class, malarial dominant vector species (DVS), study design (‡ indicate that study was performed solely in children), number of participants and number of samples, number of salivary antibody outcome observations taken from study (Meta-N), entomological and malariometric indices and salivary antibody outcomes assessed. Endemicity is derived from *P. falciparum* prevalence rate in 2-10 year olds (*Pf*PR₂₋₁₀) from Malaria Atlas Project (MAP) using site geolocations and year of study, using established cut offs reported in Bhatt *et al.* [20]. If *Pf*PR₂₋₁₀ data were not available (*e.g.* surveys prior to 2000; or unable to determine study site geolocation and year), endemicity class is given as stated in the study (indicated by *). DVS is as stated in the study or extracted from MAP (indicated by †). Of note, *An. gambiae sensu lato* (*s.l.*) includes both *An. gambiae sensu stricto* and *An. arabiensis*. Entomological and malariometric indices include human biting rate (HBR), entomological inoculation rate (EIR), prevalence estimates of *Plasmodium* spp. (*Plas*+): detected by light microscopy (LM) or polymerase chain reaction (PCR), with § indicating prevalence of *P. falciparum* only and ¶ indicating prevalence of *P. vivax* only (no footnote indicates *P. falciparum* and *P. vivax* co-endemic), as well as *Pf*PR₂₋₁₀ extracted from MAP [54]. Salivary antibody outcomes are indicated as either seroprevalence [%] or levels [L], or both [%;L], with ^{||} indicating that studies reported results stratified by malarial infection status. Salivary antigens include recombinant full-length proteins, synthetic peptides and whole salivary gland extracts (SGE). Italicised prefix of salivary antigen indicates species: *An. gambiae* (*g*), *An. funestus* (*f*), *An. alarlingi* (*d*), *An. alarlingi* (*d*), *An. alarlingi* (*d*), *An. darlingi* (*d*), *An. dar*

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Generalised multilevel modelling of 132 meta-observations from 12 studies estimated a positive association between Anopheles spp.-HBR and seroprevalence of IgG to An. gambiae gSG6 salivary antigen [5, 7, 8, 10, 11, 13, 29, 33, 36, 38, 39, 53]. The magnitude of the association was such that a 50% relative increase in HBR was associated with a 13% increase (OR: 1.13; 95%CI: 1.06-1.20, p<0.001) in the odds of anti-gSG6 IgG seropositivity (Figure 2 and Figure 2 – Supplement 1). As the association between gSG6 IgG and HBR (log transformed) is non-linear, relative change in gSG6 IgG will vary across HBR levels. To quantify this, we estimated odds ratios for different incremental per cent increases in HBR, shown in Figure 3A. Heterogeneity in the effect of HBR on gSG6 across studies was observed (likelihood ratio $\chi^2(1) = 109.25$, p < 0.001); the 95% reference range of study-specific effects for a 50% relative increase in HBR ranged from a 7% reduction to a 37% increase in odds (OR: 0.93-1.37). There was no evidence (p=0.443) that the association between HBR and gSG6 IgG varied according to vector collection method (human landing catch or other indirect methods). However, the magnitude of the association between An. gambiae gSG6 IgG seropositivity and HBR was greatest where An. gambiae s.l. was the only dominant vector (p<0.001); a 50% relative increase in HBR was associated with a 20% increase (OR: 1.20; 95%CI: 1.11-1.31; p<0.001) in the odds of gSG6 IgG seropositivity, compared to an 8% (OR: 1.08; 95% CI: 0.99-1.18; p=0.079) and 3% (OR: 1.03; 95% CI: 1.02-1.05; p<0.001) increase in odds of gSG6 IgG seropositivity where other DVS were present in addition to An. gambiae s.l. and where An. gambiae s.l. was absent, respectively (Figure 4; Figure 4 – Supplement 1). In order to quantify the relationship between gSG6 IgG seroprevalence and HBR, for given HBR values we estimated gSG6 IgG seroprevalence by producing model-based predicted probabilities overall and by DVS (Figure 4). Where An. gambiae s.l is the only DVS, predicted seroprevalence of An. gambiae gSG6 ranged from 8% (95%CI: 0-22%) to 86% (95%CI: 67-100%) for an HBR of 0.01 to 100 bites per person per night respectively.




Figure 2. Association between anti-gSG6 IgG seroprevalence and human biting rate (HBR). Figure shows the observed anti-gSG6 IgG (either recombinant or peptide form) seroprevalence (%) and HBR for each meta-observation, as well as the predicted average anti-gSG6 IgG seroprevalence (predicted probability for the average study and country) with 95% confidence intervals (95%CI). Circles are proportional to the size of the sample for each meta-observation. Association estimated using generalised multilevel mixed-effects modelling to account for the hierarchical nature of the data, using an anti-gSG6 IgG meta-observation, nested within study nested in country (model output shown in Figure 2 – Supplement 1; p<0.001). Note: to aid visualisation the graph is truncated to show 75% of HBR data (i.e. 75th percentile 12.2 bites per person per night) but HBR estimates up to 121.4 were observed and analysed.

199

200

201

202


203

204

205

206

207



210

211

212

213

214

215

Figure 3. Estimated change in odds of anti-gSG6 IgG seropositivity for given per cent increases in A) HBR (bites/person/night) and B) EIR (infective bites/person/year). Forest plots show estimated odds ratios (ORs) with 95% confidence intervals for given per cent increases in HBR or EIR, estimated using generalised multilevel mixed-effects modelling of the association between anti-gSG6 IgG seropositivity and log HBR or EIR, with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of HBR or EIR (see Figure 2 – Supplement 1 and Figure 3 – Supplement 1 for model output).




Figure 4. Forest plots of predicted anti-gSG6 IgG seroprevalence (%) and Anopheles speciesspecific human biting rate (HBR). Panels show the predicted average anti-gSG6 IgG seroprevalence (predicted probability for the average study and country) with 95% confidence intervals for given HBR, for all Anopheles spp. (using model output from Figure 2 – Supplement 1) and for specific-dominant vector species (DVS): where An. gambiae s.l. is the only DVS, where other DVS were present in addition to An. gambiae s.l. and where An. gambiae s.l. was absent (using model output from Figure 4 - Supplement 1).

218

219

220

221

222

223

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

A positive association was also found between seroprevalence of anti-gSG6 IgG antibodies and EIR in analysis of 38 observations from eight studies (Figure 3B, Figure 3 – Supplement 1) [3, 9, 13, 29, 39-41, 53]. For a 50% increase in EIR, the odds of anti-gSG6 IgG seropositivity increased by 6% (OR: 1.06; 95%CI: 1.03-1.10; p<0.001), with heterogeneity in the study-specific effects (95% reference range: 1.00-1.13; likelihood ratio $\chi^2(1) = 15.02$, p < 0.001). There was no evidence of effect modification by either vector collection method (p=0.095) or DVS (p=0.800) on the association between seroprevalence of anti-gSG6 IgG and EIR. Similar positive associations were also found between anti-gSG6 IgG levels, HBR and EIR in 11 studies [7-11, 29, 36, 37, 39, 42, 52] and three studies [9, 13, 39] respectively but seven studies showed no association between HBR and levels of IgG to gSG6 [5, 13, 32, 33, 38, 43, 53]. The association between anti-gSG6 IgG seroprevalence and population-level prevalence of Plasmodium spp. infection was investigated. Generalised multilevel modelling of 212 metaobservations from 14 studies [3, 5, 9, 13, 15, 29, 30, 33, 35, 36, 38, 41, 47, 51] showed that for a 10% relative increase in the prevalence of *Plasmodium* spp. infection the odds of gSG6 IgG seropositivity increased by 4%, although the confidence intervals were wide (OR: 1.04; 95%CI: 0.98-1.11; p=0.148) (Figure 5 and Figure 5 – Supplement 1). In the association between gSG6 IgG seropositivity and *Plasmodium* spp. infection, there was no evidence for a moderating effect of *Plasmodium* spp. detection method (light microscopy, or PCR, p=0.968) or species (P. falciparum and P. vivax, or P. falciparum,

p=0.586) potentially because all studies that reported P. vivax were co-prevalent with P. falciparum.




Figure 5. The association between anti-gSG6 IgG seroprevalence (%) and Plasmodium spp. prevalence (%). Figure shows the observed anti-gSG6 IgG (either recombinant or peptide form) seroprevalence (%) and prevalence of any *Plasmodium* spp. infection (%) for each meta-observation, as well as the predicted average anti-gSG6 IgG seroprevalence (predicted probability for average study) with 95% confidence intervals (95% CI). Circles are proportional to the size of the sample for each metaobservation. Association estimated using generalised multilevel mixed-effects modelling to account for the hierarchical nature of the data, using an anti-gSG6 IgG meta-observation, nested within study. See Figure 5 – Supplement 1 for model output.

245

246

247

248

249

250

251

252

253

254

255

256

257

Additionally, 14 studies reported estimates of anti-gSG6 IgG levels and the prevalence of *Plasmodium* spp. infections. The median anti-gSG6 IgG antibody levels increased with increasing *Plasmodium* spp. prevalence in six of these studies [5, 13, 15, 37, 38, 51], or in Plasmodium spp. infected compared to non-infected individuals [12, 50], but showed no association in eight studies [9, 29, 30, 32, 33, 35, 36,

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276 277

278

279

280 281

282

283

284

43]. Furthermore, we also investigated associations with serological measures of malaria exposure and found that for a 10% relative increase in pre-erythrocytic and blood-stage stage antigen seroprevalence there was an 11% (OR: 1.11; 95% CI: 1.02-1.21%, p=0.013) and 5-27% (OR range: 1.05-1.27; p range: <0.001 to 0.523) increase in the odds of anti-gSG6 IgG seropositivity, respectively (Supplementary File 3).

To give epidemiological context we estimated anti-gSG6 seroprevalence by producing model-based predicted probabilities by malarial endemicity class. Multilevel modelling on 297 meta-observations from 22 studies shows that the estimated anti-gSG6 IgG seroprevalence is higher for the higher endemicity classes (eliminating malaria: 20% (95%CI: 8-31%); hypoendemic: 34% (95%CI: 19-49%); mesoendemic: 52% (95%CI: 35-68%); hyperendemic settings: 47% (95%CI: 27-64%); holoendemic: 78% (95%CI: 67-90%); p<0.001; Table 2). In addition, using Bayes Best-Linear-Unbiased Predictions (BLUPs) we estimated country-specific gSG6 IgG seroprevalence from an intercept only multilevel model fitted to 301 meta-observations from 22 studies. It showed that IgG seroprevalence to An. gambiae gSG6 was lowest in countries in the Pacific Region where An. gambiae is absent (Vanuatu (31%) and Solomon Islands (32%)) and highest in countries where An. gambiae is a DVS (Benin (72%) and Burkina Faso (65%); Supplementary File 4).

Table 2: Association between gSG6 IgG seroprevalence (%) and malarial endemicity (PfPR₂₋₁₀).

Malaria Endemicity Class ^a	OR	95%CI	<i>p</i> -value	Predicted gSG6 IgG seroprevalence (%)	95%CI
Eliminating malaria(PfPR <1%)	Ref.			20.0	8.3, 31.7
Hypoendemic _(PfPR 1-10%)	2.04	1.43, 2.90	< 0.001	33.7	18.9, 48.5
Mesoendemic(PfPR 10-50%)	4.19	2.80, 6.08	< 0.001	51.5	34.6, 67.7
Hyperendemic _(PfPR 50-75%)	3.36	1.98, 5.71	< 0.001	46.5	27.4, 63.8
Holoendemic _(PfPR >75%)	14.4	9.72, 21.36	< 0.001	78.2	66.8, 89.7

Table shows the odds ratio (OR), 95% confidence interval (95%CI), p-value, as well as the predicted gSG6 IgG seroprevalence and associated 95%CIb for associations between endemicity class (derived from P. falciparum parasite rates in 2-10 year olds (PfPR₂₋₁₀)) and anti-gSG6 IgG seropositivity.

^a Generalised multilevel modelling estimating the association between anti-gSG6 IgG seropositivity and endemicity class with random-effects for study-specific heterogeneity in gSG6 IgG. Model fitted to n=297 meta-observations. Endemicity class membership is derived from PfPR₂₋₁₀ from MAP, using cut-offs taken from Bhatt et al. [20], or where MAP data were unavailable, endemicity was included as indicated in the study.

^b Predicted gSG6 IgG seroprevalence (predicted probability in the average study) is estimated from generalised multilevel modelling

Assessments of internal and external study validity revealed there was a moderate risk of selection bias (Supplementary File 2) due to the study-specific inclusion criteria of populations at higher risk of malaria which contributed gSG6 seroprevalence estimates.

Discussion

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

This systematic review and multilevel modelling analysis provides the first quantification of a positive non-linear association between seroprevalence of An. gambiae gSG6 IgG antibodies and HBR and demonstrated that its magnitude varied with respect to the DVS present in the area. Importantly, this review identified a paucity of studies conducted outside of Africa, as well as investigating salivary antigens representing different Anopheles spp. and antigenic targets. gSG6 antibodies were positively associated with the prevalence of *Plasmodium* spp. infection as well as established epidemiological measures of malaria transmission: malaria endemicity class and EIR. Overall, our results demonstrate that antibody seroprevalence specific for Anopheles spp. salivary antigens has the potential to be an effective measure of vector exposure and malaria transmission at the population- and, potentially, individual-level. An. gambiae gSG6 IgG seropositivity increased with increasing HBR, although these increases had diminishing impact on An. gambiae gSG6 IgG seropositivity at higher levels of HBR. We also observed that the association was strongest in areas where An. gambiae s.l. was the only DVS (that is concordant An. gambiae species-specific HBR with An. gambiae gSG6 antibodies). Associations, albeit weaker, were also observed between discordant species-specific HBR and gSG6, most likely because the An. gambiae SG6 gene shares moderate sequence identity with vector species that are dominant in other regions (Africa: 80% An. funestus; Asia: 79% An. stephensi and An. maculatus; 54% An. dirus; Pacific: 52.5% An. farauti), and is absent from the DVS of the Americas (An. albimanus and An. darlingi) [55]. The generalisability of An. gambiae gSG6 IgG as a biomarker of exposure to other Anopheles spp. may therefore be limited. However, our review also identified a paucity of studies investigating additional salivary antigenic targets and Anopheles species not present in Africa. The identification of novel salivary antigens that are species-specific will be valuable in quantifying exposure to the other

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

Anopheles vectors that share limited identity with An. gambiae SG6 (such as An. farauti and An. dirus), as well as Anopheles spp. which lack SG6 (as done for An. albimanus and An. darlingi [49, 56]). An Anopheles specific serological platform could advance vector surveillance by more accurately capturing exposure to DVS in the South American and Asia Pacific regions which exhibit diverse biting behaviours and vector competence (DVS typically bite outdoors during the night and day respectively [19, 57-61]), as well as the increasing threat of urban malaria from An. stephensi in Africa [62, 63]. Importantly, this review demonstrated that the prevalence of *Anopheles* salivary antibodies increased with increasing prevalence of *Plasmodium* spp. infection as well as established epidemiological measures of malaria transmission: malaria endemicity class and EIR. Anti-salivary antibodies, such as SG6 IgG, therefore, have the potential to serve as a proxy measure for vectorial capacity and malaria receptivity of a population to sustain malaria transmission. Their application could be particularly relevant in pre-elimination areas, or non-endemic areas under threat of imported malaria, where Anopheles salivary antibodies are more readily detectable than parasites; salivary antibodies were predicted to be prevalent (20%) in areas defined as eliminating malaria (<1% PfPR₂₋₁₀). Furthermore, if SG6 IgG seroprevalence can be effectively combined with a measurement of the sporozoite index, salivary antibodies as a marker of HBR could help overcome sensitivity limitations of EIR in low transmission areas. Additional measures could include estimates of malaria prevalence or serological biomarkers that are species- or life stage-specific (e.g. *Plasmodium* spp. pre-erythrocytic antigens as biomarkers for recent parasite inoculation). Indeed, positive associations between antibodies specific for Plasmodium spp. pre-erythrocytic and blood-stage antigens with gSG6 were demonstrated in analyses of data from diverse malaria endemic areas. Serological tools combining salivary antigens with antigens specific for the different *Plasmodium* spp. would be particularly beneficial in the Asia Pacific, a region of relatively low malaria transmission with goals of elimination, but the highest burden of P. vivax malaria where blood-stage infection can be caused by relapses from dormant liver stages. In these areas, parasite prevalence may therefore overestimate ongoing malaria transmission, making vector surveillance tools essential to informing elimination strategies in the Asia Pacific and other regions where *P. vivax* is endemic.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

The gold standard entomological measures HBR and EIR provide crude population-level estimates of vector and malaria exposure that are specific in space and time and preclude investigation of individuallevel heterogeneity and natural transmission dynamics. Our study demonstrated that salivary biomarkers measured at the individual-level, such as gSG6 IgG, can be used to quantify total vector exposure at the population-level, without requiring laborious entomological experiments. However, validating an individual-level serological measure, which demonstrates considerable individual-level variation, against the imperfect population-level gold standards of HBR and EIR is challenging and reflected in the variation in study-specific estimates in the association between gSG6 IgG and HBR in modelling analyses. However, the accuracy of salivary antibodies to measure individual-level exposure to Anopheles bites is yet to be validated; literature searches identified no studies investigating this association at the individual-level. Without detailed measurements of individual-level vector exposure, or a detailed knowledge of the half-life of *Anopheles* salivary antibodies post biting event, the true accuracy of salivary antibodies, such as SG6 IgG, to measure individual-level HBR remains unknown. This knowledge is particularly pertinent where Anopheles salivary biomarkers might be applied to assess the effectiveness of a vector control intervention or used to measure temporal changes in malaria transmission; particularly in areas or populations where there is considerable heterogeneity in individual-level risk of Anopheles exposure (e.g. unmeasured outdoor biting due to occupational exposure for forest workers [64]). The broad nature of our inclusion and quality criteria was a key strength of our systematic review, which aimed to provide a comprehensive analysis of all Anopheles salivary biomarkers and determine their associations with entomological and malariometric measures of transmission. However, this review has two main limitations. First, despite the inclusive nature, assessment of the external validity of the review revealed a moderate risk of bias; some studies exhibited a high risk of selection bias as they were performed in specific high-risk populations not representative of the overall population (i.e. children only). This is accounted for to some degree by specification of a random effect (i.e. intercept) for study, which accounts for unmeasured study-specific factors that may introduce study-specific measurement error to measurement of the outcome. Second, with respect to internal validity, there may be potential selection bias introduced by the exclusion of studies reporting zero HBR (seven observations from three studies [9, 36, 53]), EIR (22 observations from three studies [9, 13, 29]) and malaria prevalence (15 observations from three studies [15, 36, 51]) estimates, given we modelled the log of these factors. However, adding a small constant (*e.g.* 0.001) to a zero value to permit modelling of a log estimate can also introduce considerable bias (*i.e.* seemingly small differences between values become very large on the log scale). In light of this, we also chose to provide estimates of association and gSG6 IgG seroprevalence according to widely accepted, discrete, endemicity classes (which permitted inclusion of all studies) and according to a selected range of epidemiologically relevant hypothetical HBR's (no widely accepted HBR classification exists in the literature) to provide epidemiological context.

Conclusions

In order to advance progress towards malaria elimination the World Health Organisation has called for innovative tools and improved approaches to enhance vector surveillance and monitoring and evaluation of interventions [65]. Our systematic review has provided strong evidence that *Anopheles* salivary antibodies are serological biomarkers of vector and malaria exposure, by quantifying their strong positive association with *Anopheles*-HBR and established epidemiological measures of malaria transmission. These salivary biomarkers have the potential to replace crude population-level entomological experiments with a precise and scalable tool that measures *Anopheles* vector exposure at the individual-level. This approach could be expanded into a sero-surveillance tool to assess the effectiveness of vector control interventions, define heterogeneity in malaria transmission and inform efficient resource-allocation, that would ultimately accelerate progress towards elimination.

Contributors

All authors developed the protocol and the analytical plan. EAK performed literature searches, screened studies and extracted data with input from FJIF. EAK and PAA analysed the data. All authors interpreted the data. EAK and FJIF drafted the report. All authors read and critically revised the draft report, and approved the final report. All authors agreed to be accountable for all aspects of the work.

Declaration of interests

We declare no competing interests.

Acknowledgements

We wish to thank the authors of the original studies for responding to requests for further information/data for inclusion in the systematic review.

information data for inclusion in the systematic reviews

analysis, decision to publish, or preparation of the manuscript.

This work was supported by the National Health and Medical Research Council of Australia (Australian Centre for Research Excellence in Malaria Elimination (ACREME) to FJIF and JAS (1134989); Career Development Fellowship to FJIF (1166753) and investigator award to JAS (1196068); and its Independent Research Institute Infrastructure Support Scheme), the Australian Commonwealth Government (Australian Government Research Training Program Scholarship awarded to EK) and a Victorian State Government Operational Infrastructure Support Program received by the Burnet Institute. This research was funded in part by the Wellcome Trust (220211). For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The funders had no role in the study design, data collection or

References

405

429

430

- 406 1. Monroe A, Moore S, Okumu F, Kiware S, Lobo NF, Koenker H, Sherrard-Smith E, Gimnig J, Killeen GF. Methods and indicators for measuring patterns of human exposure to malaria vectors. Malar J. 2020;19(1):207. doi: 10.1186/s12936-020-03271-z.
- 409 2. Mathenge EM, Misiani GO, Oulo DO, Irungu LW, Ndegwa PN, Smith TA, Killeen GF, Knols BGJ.
 410 Comparative performance of the Mbita trap, CDC light trap and the human landing catch in the sampling of
 411 *Anopheles arabiensis*, *An. funestus* and *culicine* species in a rice irrigation in western Kenya. Malar J. 2005;4.
 412 doi: 10.1186/1475-2875-4-7. PubMed PMID: 15667666.
- 3. Badu K, Siangla J, Larbi J, Lawson BW, Afrane Y, Ong'echa J, Remoue F, Zhou G, Githeko AK, Yan G. Variation in exposure to *Anopheles gambiae* salivary gland peptide (gSG6-P1) across different malaria transmission settings in the western Kenya highlands. Malar J. 2012;11:318. doi: 10.1186/1475-2875-11-318.
- 416 4. Drame PM, Diallo A, Poinsignon A, Boussari O, Dos Santos S, Machault V, Lalou R, Cornelie S, LeHesran JY, Remoue F. Evaluation of the effectiveness of malaria vector control measures in urban settings of Dakar by a specific *Anopheles* salivary biomarker. PLoS One. 2013;8(6):e66354. doi: 10.1371/journal.pone.0066354.
- 5. Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Toto JC, Foumane V, Dos-Santos MA, Sembène M, Fortes F, Simondon F, Carnevale P, Remoue F. Human antibody responses to the *Anopheles* salivary gSG6-P1 peptide: a novel tool for evaluating the efficacy of ITNs in malaria vector control. PLoS One. 2010;5(12):e15596. doi: 10.1371/journal.pone.0015596.
- Drame PM, Poinsignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, Cornelie S, Foumane V,
 Toto JC, Sembene M, Boulanger D, Simondon F, Fortes F, Carnevale P, Remoue F. Human antibody response to
 Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated
 nets in malaria vector control. Am J Trop Med Hyg. 2010;83(1):115-21. doi: 10.4269/ajtmh.2010.09-0684.
 Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, Massougbodji A, Cornélie
 - 7. Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, Massougbodji A, Cornélie S, Courtin D, Migot-Nabias F, Garcia A, Remoué F. Specific antibodies to *Anopheles* gSG6-P1 salivary peptide to assess early childhood exposure to malaria vector bites. Malar J. 2015;14:285. doi: 10.1186/s12936-015-0800-6.
- 432 8. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nèbiè I, Petrarca V, Modiano D, Arcà B. Wide cross-reactivity between *Anopheles gambiae* and *Anopheles funestus* SG6 salivary proteins supports exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa. Malar J. 2011;10:206. doi: 10.1186/1475-2875-10-206.
- 436 9. Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinsignon A, Sirima SB, Nèbiè I, Lombardo F, Remoue F, Coluzzi M, Petrarca V, Modiano D, Arcà B. Humoral response to the *Anopheles gambiae* salivary protein gSG6: a serological indicator of exposure to Afrotropical malaria vectors. PLoS One. 2011;6(3):e17980. doi: 10.1371/journal.pone.0017980.
- 440 10. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arcà B, Drakeley C. IgG responses to *Anopheles gambiae* salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 2012;7(6):e40170. doi: 10.1371/journal.pone.0040170.
- 11. Drame PM, Machault V, Diallo A, Cornélie S, Poinsignon A, Lalou R, Sembène M, Dos Santos S, Rogier C, Pagès F, Le Hesran JY, Remoué F. IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to *Anopheles* bites in urban areas of Dakar region, Sénégal. Malar J. 2012;11:72. doi: 10.1186/1475-2875-11-72.
- Londono-Renteria B, Drame PM, Weitzel T, Rosas R, Gripping C, Cardenas JC, Alvares M, Wesson DM, Poinsignon A, Remoue F, Colpitts TM. *An. gambiae* gSG6-P1 evaluation as a proxy for human-vector contact in the Americas: a pilot study. Parasit Vectors. 2015;8:533. doi: 10.1186/s13071-015-1160-3.
- 451 13. Ya-Umphan P, Cerqueira D, Parker DM, Cottrell G, Poinsignon A, Remoue F, Brengues C, Chareonviriyaphap T, Nosten F, Corbel V. Use of an *Anopheles* salivary biomarker to assess malaria transmission risk along the Thailand-Myanmar Border. J Infect Dis. 2017;215(3):396-404. doi: 10.1093/infdis/jiw543.
- 14. Noukpo MH, Damien GB, Elanga-N'Dille E, Sagna AB, Drame PM, Chaffa E, Boussari O, Corbel V, Akogbéto M, Remoue F. Operational assessment of long-lasting insecticidal nets by using an *Anopheles* salivary
- 456 biomarker of human-vector contact. Am J Trop Med Hyg. 2016;95(6):1376-82. doi: 10.4269/ajtmh.15-0541.
- 457 15. Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, Arcà B, Drakeley C, Kaneko A.
- 458 Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit
- 459 Vectors. 2017;10(1):204. doi: 10.1186/s13071-017-2139-z.

- 460 16. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews
- 461 and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 462 10.1371/journal.pmed.1000097.
- 463 17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA,
- Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of
- Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. Epub 2000/05/02. doi:
- 466 10.1001/jama.283.15.2008. PubMed PMID: 10789670.
- 467 18. Yamba EI, Tompkins AM, Fink AH, Ermert V, Djouda A, Amekudzi LK, Briët OJT. Monthly entomological inoculation rates for studying malaria transmission seasonality in Africa. PANGAEA; 2018.
- The Malaria Atlas Project [Internet]. 2017. Available from: https://malariaatlas.org/.
- 470 20. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A,
- Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA,
- Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of
- 473 malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11.
- 474 Epub 2015/09/16. doi: 10.1038/nature15535. PubMed PMID: 26375008.
- Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis.
- 477 Lancet Glob Health. 2019;7(8):e1020-e30. doi: 10.1016/S2214-109X(19)30255-4.
- Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk
- of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin
- 480 Epidemiol. 2012;65(9):934-9. doi: 10.1016/j.jclinepi.2011.11.014.
- 481 23. Lawaly R, Konate L, Marrama L, Dia I, Diallo D, Sarr FD, Schneider BS, Casademont I, Diallo M, Brey
- PT, Sakuntabhai A, Mecheri S, Paul R. Impact of mosquito bites on asexual parasite density and gametocyte
- prevalence in asymptomatic chronic *Plasmodium falciparum* infections and correlation with IgE and IgG titers. Infect Immun. 2012;80(6):2240-6. doi: 10.1128/iai.06414-11. PubMed PMID: WOS:000304387700031.
- 484 inject immun. 2012;80(6):2240-6. doi: 10.1128/iai.00414-11. Pubiwed PMID: WOS:000304387/00031.
- 485 24. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Modiano D, Arcà B.
- Differential antibody response to the *Anopheles gambiae* gSG6 and cE5 salivary proteins in individuals naturally
- 487 exposed to bites of malaria vectors. Parasit Vectors. 2014;7:549. doi: 10.1186/s13071-014-0549-8.
- 488 25. Rizzo C, Ronca R, Lombardo F, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Troye-Blomberg M,
- Modiano D, Arcà B. IgG1 and IgG4 antibody responses to the *Anopheles gambiae* salivary protein gSG6 in the sympatric ethnic groups Mossi and Fulani in a malaria hyperhendemic area of Burkina Faso. PLoS One.
- 491 2014;9(4):e96130. doi: 10.1371/journal.pone.0096130.
- 492 26. Waitayakul A, Somsri S, Sattabongkot J, Looareesuwan S, Cui L, Udomsangpetch R. Natural human
- humoral response to salivary gland proteins of *Anopheles* mosquitoes in Thailand. Acta Trop. 2006;98(1):66-73.
- 494 doi: 10.1016/j.actatropica.2006.02.004.
- 495 27. Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet F, Remoue F, Allan R,
- Fortes F, Carnevale P, Manguin S. Human antibody response to *Anopheles* saliva for comparing the efficacy of three malaria vector control methods in Balombo, Angola. PLoS One. 2012;7(9):e44189. doi:
- 498 10.1371/journal.pone.0044189.
- 499 28. Marie A, Ronca R, Poinsignon A, Lombardo F, Drame PM, Cornelie S, Besnard P, Le Mire J, Fiorentino
- 500 G, Fortes F, Carnevale P, Remoue F, Arcà B. The Anopheles gambiae cE5 salivary protein: a sensitive biomarker
- to evaluate the efficacy of insecticide-treated nets in malaria vector control. Microbes Infect. 2015;17(6):409-16.
- 502 doi: 10.1016/j.micinf.2015.01.002.
- 503 29. Soma DD, Kassié D, Sanou S, Karama FB, Ouari A, Mamai W, Ouédraogo GA, Salem G, Dabiré RK,
- Fournet F. Uneven malaria transmission in geographically distinct districts of Bobo-Dioulasso, Burkina Faso.
- 505 Parasit Vectors. 2018;11(1):296. doi: 10.1186/s13071-018-2857-x.
- 506 30. Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, Ehouman MF, Gnamien L, Richard
- V, Djaman JA, Perraut R. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory
- 508 Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIXTM). Malar J.
- 509 2015;14:509. doi: 10.1186/s12936-015-1043-2.
- 510 31. Koffi D, Varela ML, Loucoubar C, Beourou S, Vigan-Womas I, Touré A, Djaman JA, Touré AO, Perraut
- R. Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission
- 512 in peri-urban area of Cote d'Ivoire between 2010 and 2013. PLoS One. 2017;12(2):e0172899. doi:
- 513 10.1371/journal.pone.0172899.
- 514 32. Traoré DF, Sagna AB, Adja AM, Zoh DD, Lingué KN, Coulibaly I, N'Cho Tchiekoi B, Assi SB,
- 515 Poinsignon A, Dagnogo M, Remoue F. Evaluation of malaria urban risk using an immuno-epidemiological
- 516 biomarker of human exposure to Anopheles bites. Am J Trop Med Hyg. 2018;98(5):1353-9. doi:
- 517 10.4269/ajtmh.17-0231.
- 518 33. Traoré DF, Sagna AB, Adja AM, Zoh DD, Adou KA, Lingué KN, Coulibaly I, Tchiekoi NB, Assi SB,
- Poinsignon A, Dagnogo M, Remoue F. Exploring the heterogeneity of human exposure to malaria vectors in an

- 520 urban setting, Bouaké, Côte d'Ivoire, using an immuno-epidemiological biomarker. Malar J. 2019;18(1):68. doi:
- 521 10.1186/s12936-019-2696-z.
- 522 34. Sadia-Kacou CAM, Yobo CM, Adja MA, Sagna AB, Ndille EE, Poinsignon A, Tano Y, Koudou BG,
- Remoue F. Use of *Anopheles* salivary biomarker to assess seasonal variation of human exposure to *Anopheles*
- 524 bites in children living near rubber and oil palm cultivations in Côte d'Ivoire. Parasite Epidemiol Control.
- 525 2019;5:e00102. doi: 10.1016/j.parepi.2019.e00102.
- 526 35. Badu K, Gyan B, Appawu M, Mensah D, Dodoo D, Yan G, Drakeley C, Zhou G, Owusu-Dabo E, Koram
- 527 KA. Serological evidence of vector and parasite exposure in Southern Ghana: the dynamics of malaria
- 528 transmission intensity. Parasit Vectors. 2015;8:251. doi: 10.1186/s13071-015-0861-y.
- 529 36. Sagna AB, Sarr JB, Gaayeb L, Drame PM, Ndiath MO, Senghor S, Sow CS, Poinsignon A, Seck M,
- Hermann E, Schacht A-M, Faye N, Sokhna C, Remoue F, Riveau G. gSG6-P1 salivary biomarker discriminates
- micro-geographical heterogeneity of human exposure to *Anopheles* bites in low and seasonal malaria areas. Parasit
- 532 Vectors. 2013;6(1):68. doi: 10.1186/1756-3305-6-68.
- 533 37. Poinsignon A, Samb B, Doucoure S, Drame PM, Sarr JB, Sow C, Cornelie S, Maiga S, Thiam C, Rogerie
- F, Guindo S, Hermann E, Simondon F, Dia I, Riveau G, Konate L, Remoue F. First attempt to validate the gSG6-
- P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to *Anopheles funestus* bites. Trop Med Int Health. 2010;15(10):1198-203. doi: 10.1111/j.1365-3156.2010.02611.x.
- 537 38. Sarr JB, Samb B, Sagna AB, Fortin S, Doucoure S, Sow C, Senghor S, Gaayeb L, Guindo S, Schacht
- AM, Rogerie F, Hermann E, Dia I, Konate L, Riveau G, Remoue F. Differential acquisition of human antibody
- responses to *Plasmodium falciparum* according to intensity of exposure to *Anopheles* bites. Trans R Soc Trop
- 540 Med Hyg. 2012;106(8):460-7. doi: 10.1016/j.trstmh.2012.05.006.
- 39. Ali ZM, Bakli M, Fontaine A, Bakkali N, Vu Hai V, Audebert S, Boublik Y, Pagès F, Remoué F, Rogier
- 542 C, Fraisier C, Almeras L. Assessment of *Anopheles* salivary antigens as individual exposure biomarkers to species-specific malaria vector bites. Malar J. 2012;11:439. doi: 10.1186/1475-2875-11-439.
- 544 40. Ambrosino E, Dumoulin C, Orlandi-Pradines E, Remoue F, Toure-Baldé A, Tall A, Sarr JB, Poinsignon
- A, Sokhna C, Puget K, Trape JF, Pascual A, Druilhe P, Fusai T, Rogier C. A multiplex assay for the simultaneous
- detection of antibodies against 15 *Plasmodium falciparum* and *Anopheles gambiae* saliva antigens. Malar J. 2010;9:317. doi: 10.1186/1475-2875-9-317.
- 548 41. Perraut R, Varela ML, Loucoubar C, Niass O, Sidibé A, Tall A, Trape JF, Wotodjo AN, Mbengue B,
- Sokhna C, Vigan-Womas I, Touré A, Richard V, Mercereau-Puijalon O. Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One.
- 551 2017;12(6):e0179146. doi: 10.1371/journal.pone.0179146.
- 552 42. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B,
- Sokhna C, Arcà B, Simondon F, Remoue F. Novel peptide marker corresponding to salivary protein gSG6
- potentially identifies exposure to *Anopheles* bites. PLoS One. 2008;3(6):e2472. doi: 10.1371/journal.pone.0002472.
- Poinsignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, Sokhna C, Cisse B, Simondon F, Remoue F. Human IgG response to a salivary peptide, gSG6-PI, as a new immuno-epidemiological tool for
- evaluating low-level exposure to *Anopheles* bites. Malar J. 2009;8. doi: 10.1186/1475-2875-8-198. PubMed
- 559 PMID: WOS:000269875000001.
- 560 44. Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F. Evaluation of the antibody
- response to *Anopheles* salivary antigens as a potential marker of risk of malaria. Trans R Soc Trop Med Hyg. 2006;100(4):363-70. doi: 10.1016/j.trstmh.2005.06.032.
- 563 45. Sagna AB, Kassié D, Couvray A, Adja AM, Hermann E, Riveau G, Salem G, Fournet F, Remoue F.
- Spatial assessment of contact between humans and *Anopheles* and *Aedes* mosquitoes in a medium-sized African
- urban setting, using salivary antibody-based biomarkers. J Infect Dis. 2019;220(7):1199-208. doi: 10.1093/infdis/jiz289.
- 567 46. Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M, Bostrom S, Ronca R, Rooth I,
- Farnert A. Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.
- 569 Sci Rep. 2016;6. doi: 10.1038/srep19472. PubMed PMID: WOS:000369380100001.
- 570 47. Proietti C, Verra F, Bretscher MT, Stone W, Kanoi BN, Balikagala B, Egwang TG, Corran P, Ronca R,
- 571 Arcà B, Riley EM, Crisanti A, Drakeley C, Bousema T. Influence of infection on malaria-specific antibody
- dynamics in a cohort exposed to intense malaria transmission in northern Uganda. Parasite Immunol. 2013;35(5-
- 573 6):164-73. doi: 10.1111/pim.12031.
- 574 48. Andrade BB, Rocha BC, Reis-Filho A, Camargo LM, Tadei WP, Moreira LA, Barral A, Barral-Netto
- M. Anti-Anopheles darlingi saliva antibodies as marker of Plasmodium vivax infection and clinical immunity in
- 576 the Brazilian Amazon. Malar J. 2009;8:121. doi: 10.1186/1475-2875-8-121.
- 577 49. Londono-Renteria B, Drame PM, Montiel J, Vasquez AM, Tobón-Castaño A, Taylor M, Vizcaino L,
- 578 Lenhart AAE. Identification and pilot evaluation of salivary peptides from Anopheles albimanus as biomarkers
- for bite exposure and malaria infection in Colombia. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21030691.

- 580 50. Montiel J, Carbal LF, Tobón-Castaño A, Vásquez GM, Fisher ML, Londono-Rentería B. IgG antibody
- response against *Anopheles* salivary gland proteins in asymptomatic *Plasmodium* infections in Narino, Colombia.
- 582 Malar J. 2020;19(1):42. doi: 10.1186/s12936-020-3128-9.
- 583 51. Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, Tsuboi T, Sochantha T, Sovannaroth S,
- Ménard D, Coosemans M, Durnez L. Serological markers to measure recent changes in malaria at population
- 585 level in Cambodia. Malar J. 2016;15(1):1-18. doi: 10.1186/s12936-016-1576-z.
- 586 52. Charlwood JD, Hall T, Nenhep S, Rippon E, Branca-Lopes A, Steen K, Arca B, Drakeley C. Spatial repellents and malaria transmission in an endemic area of Cambodia with high mosquito net usage. MalariaWorld
- 588 J. 2017;8(11).
- 589 53. Pollard EJM, Patterson C, Russell TL, Apairamo A, Oscar J, Arcà B, Drakeley C, Burkot TR. Human
- exposure to *Anopheles farauti* bites in the Solomon Islands is not associated with IgG antibody response to the gSG6 salivary protein of *Anopheles gambiae*. Malar J. 2019;18(1):334. doi: 10.1186/s12936-019-2975-8.
- 592 54. *Plasmodium falciparum* Paratsite Rate 2-10 year olds [Internet]. MAP. 2020. Available from: https://malariaatlas.org/.
- 594 55. Arcà B, Lombardo F, Struchiner CJ, Ribeiro JM. Anopheline salivary protein genes and gene families:
- an evolutionary overview after the whole genome sequence of sixteen *Anopheles* species. BMC Genomics.
- 596 2017;18(1):153. doi: 10.1186/s12864-017-3579-8.
- 597 56. Londono-Renteria B, Montiel J, Calvo E, Tobón-Castaño A, Valdivia HO, Escobedo-Vargas K, Romero
- 598 L, Bosantes M, Fisher ML, Conway MJ, Vásquez GM, Lenhart AE. Antibody responses against Anopheles
- 599 *darlingi* immunogenic peptides in *Plasmodium* infected humans. Front Cell Infect Microbiol. 2020;10(455). doi: 10.3389/fcimb.2020.00455.
- 57. Trung HD, Bortel WV, Sochantha T, Keokenchanh K, Briët OJ, Coosemans M. Behavioural heterogeneity of Anopheles species in ecologically different localities in Southeast Asia: a challenge for vector
- 603 control. Trop Med Int Health. 2005;10(3):251-62.
- 58. Sinka ME, Bangs MJ, Manguin S, Rubio-Palis Y, Chareonviriyaphap T, Coetzee M, Mbogo CM,
- Hemingway J, Patil AP, Temperley WH. A global map of dominant malaria vectors. Parasit Vectors. 2012;5(1):69.
- 59. Sinka ME, Rubio-Palis Y, Manguin S, Patil AP, Temperley WH, Gething PW, Van Boeckel T, Kabaria
- 608 CW, Harbach RE, Hay SI. The dominant *Anopheles* vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic précis. Parasit Vectors. 2010;3(1):72. doi: 10.1186/1756-3305-3-72.
- 610 60. Herrera S, Ochoa-Orozco SA, González IJ, Peinado L, Quiñones ML, Arévalo-Herrera M. Prospects for
- malaria elimination in Mesoamerica and Hispaniola. PLoS Negl Trop Dis. 2015;9(5):e0003700. Epub 2015/05/15.
- doi: 10.1371/journal.pntd.0003700. PubMed PMID: 25973753; PubMed Central PMCID: PMCPMC4431857.
- 613 61. Chaumeau V, Fustec B, Nay Hsel S, Montazeau C, Naw Nyo S, Metaane S, Sawasdichai S,
- Kittiphanakun P, Phatharakokordbun P, Kwansomboon N, Andolina C, Cerqueira D, Chareonviriyaphap T,
- Nosten FH, Corbel V. Entomological determinants of malaria transmission in Kayin state, Eastern Myanmar: A
- 24-month longitudinal study in four villages. Wellcome Open Res. 2018;3:109. Epub 2019/06/27. doi:
- 617 10.12688/wellcomeopenres.14761.4. PubMed PMID: 31206035; PubMed Central PMCID: PMCPMC6544137.
- 618 62. Takken W, Lindsay S. Increased threat of urban malaria from *Anopheles stephensi* mosquitoes, Africa.
- 619 Emerg Infect Dis. 2019;25(7):1431-3. Epub 2019/07/17. doi: 10.3201/eid2507.190301. PubMed PMID: 620 31063455.
- 621 63. Sinka ME, Pironon S, Massey NC, Longbottom J, Hemingway J, Moyes CL, Willis KJ. A new malaria
- vector in Africa: Predicting the expansion range of *Anopheles stephensi* and identifying the urban populations at
- 623 risk. Proc Natl Acad Sci USA. 2020;117(40):24900. doi: 10.1073/pnas.2003976117.
- 624 64. Sandfort M, Vantaux A, Kim S, Obadia T, Pepey A, Gardais S, Khim N, Lek D, White M, Robinson LJ,
- 625 Witkowski B, Mueller I. Forest malaria in Cambodia: the occupational and spatial clustering of *Plasmodium vivax*
- and Plasmodium falciparum infection risk in a cross-sectional survey in Mondulkiri province, Cambodia. Malar
- 627 J. 2020;19(1):413. doi: 10.1186/s12936-020-03482-4.
- 628 65. World Health Organization. Global vector control response 2017–2030. Geneva: WHO, 2017.

Supplementary Files

Figure 2 – Supplement 1: Association between gSG6 IgG seropositivity and human biting rate...... 38 Figure 3 – Supplement 1: Association between gSG6 IgG seropositivity and entomological inoculation rate 39 Figure 4 – Supplement 1: Association between gSG6 IgG seropositivity and Human Biting Rate Figure 5 – Supplement 1. Association between gSG6 IgG seropositivity and malaria prevalence....41 Supplementary File 3. Association between gSG6 IgG seropositivity and antimalarial antibody Supplementary File 4. Country and study-specific predicted probability of gSG6 IgG seropositivity. Supplementary File 5. Association between alternative salivary biomarkers and exposures of interest.48 Supplementary References 52

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

Supplementary File 1. Supplementary Methodology. Search strategy We performed a systematic review with multilevel modelling of the published literature according to the Metaanalysis of Observational Studies in Epidemiology (MOOSE) guidelines [1] and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) specifications [2]. The protocol was registered with PROSPERO (CRD42020185449). The electronic databases PubMed, Scopus, Web of Science, African Index Medicus, and the Latin American and Caribbean Health Sciences Literature (LILACS) were searched for studies published before June 30, 2020 investigating Anopheles salivary antigens as a biomarker for mosquito exposure or malaria transmission. Search terms were as follows: Anophel* AND saliva* AND (antibod* OR sero* OR antigen OR marker* OR biomarker* OR gSG6* OR gSG* OR SG* OR cE5). The reference lists of included studies were screened for additional studies, and Google Scholar was used to identify additional works by key authors. No formal attempt was made to identify unpublished population studies as it would have required significant description of the design, methods and analysis used in these studies, and a review of ethical issues. Selection criteria The primary criteria for inclusion in this systematic review was the reporting of estimates of seroprevalence or total levels of Immunoglobulin (Ig) antibodies (including all isotypes and subclasses) in human sera against recombinant or synthetic peptide Anopheles salivary antigens. We considered for inclusion: cross-sectional studies, cohort studies, intervention studies and case-control studies of individuals or populations (including subpopulations) living in all geographies with natural exposure to Anopheles mosquitoes. Studies that were solely performed in participants not representative of the wider population (i.e. mosquito allergic patients, soldiers, returned travellers) were excluded. The minimum quality criteria for inclusion in this review were: antibody detection performed using enzyme-linked immunosorbent assay (ELISA), multiplex or Luminex assays. The exposure variables of interest included entomological and malariometric parameters, including: (i) human biting rate (HBR), defined as the number of bites received per person per unit of time; (ii) entomological inoculation rate (EIR), defined as the number of infectious bites per person per unit of time, calculated as the HBR multiplied by the sporozoite index; (iii) estimates of malaria prevalence; (iv) population-level seroprevalence estimates against Plasmodium spp. malarial antigens. To ensure HBR estimates were given for the same unit of

time (bites per person per night), biting rates given per week were divided by 7, and biting rates given per month

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

we multiplied by 12 and divided by 365. Similar approaches were employed to ensure consistent units for EIR (infectious bites per person per year). *Plasmodium* spp. infections had to be confirmed by either microscopy, rapid diagnostic test (RDT) or molecular methods (polymerase chain reaction (PCR)). Plasmodium spp. diagnosis was included for all *Plasmodium* spp. combined and the species-level if provided. Where exposure estimates were not provided, we attempted to source data from other publications by the authors, or using the site geolocation and year to obtain estimates of EIR from the Pangaea dataset [3]. P. falciparum rates in 2-10 year olds (globally, 2000–2017) and dominant vector species (DVS) from the Malaria Atlas Project (MAP) [4]. Studies of salivary antigens where exposure variables could not be sourced and data that could not be extracted were excluded. Selection of studies One author performed database searches and screened reference lists to identify possible studies. One author screened studies against inclusion criteria, with discussion and input from a second reviewer. Approaches to include all available studies The authors of any studies that did not contain relevant information on the study design, populations, eligibility criteria, or key study data, were contacted and relevant data requested. Authors were contacted via an initial email detailing the precise nature of the systematic review and the data required. If the authors did not reply to three email requests, or were unable to provide relevant data, the studies were deemed to insufficiently meet inclusion/quality criteria and were excluded. As measurement of antibody levels does not produce a common metric between studies, authors were asked to classify their participants as 'responders' or 'no-responders' according to seropositivity (antibody level relative to unexposed sera) within each study, to allow comparisons of seroprevalence between studies [5-7]. Studies that were only able to provide antibody levels or categorised seropositivity based upon arbitrary cut offs were excluded from multilevel modelling analyses and included in narrative terms. Where the salivary antibody response and exposure variable were measured in the same population and reported in multiple publications, the study with the largest sample size was included, otherwise the earliest study was included. Data extraction Data were extracted using a data collection form by one reviewer. Any data that was provided at the subpopulation level was extracted at the lowest level i.e. if a study was performed across multiple sites, and an estimate for both salivary antibody seroprevalence/levels and the outcome of interest is given for each site, it was included the site level, rather than an aggregated level.

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

Measures

Outcomes The primary outcome of interest of our systematic review was the reported antibody response (both seroprevalence and levels of all Ig subclasses and isotypes) to Anopheles salivary antigens. Multilevel modelling analyses were performed where the seroprevalence of antibodies against the same antigen and the exposure of interest were reported in more than one study. **Exposures** The primary exposures of interest included in the multilevel modelling analyses were the HBR and EIR, a measure of the average number of bites received per person per night and infectious bites received per person per year, respectively. Secondary exposures assessed include the prevalence of any *Plasmodium* spp. infection (including P. falciparum only, P. vivax only, or untyped infections). Additional secondary exposures include the P. falciparum infection rate in 2-10 year olds extracted from MAP, as well as the seroprevalence of antimalarial antibodies against pre-erythrocytic and blood-stage antigens. Clinical and methodological heterogeneity were explored using prespecified variables to minimize spurious findings. Variables considered for inclusion were study design (cohort, cross-sectional, repeated cross-sectional), DVS, study participants (adults only, children only, adults and children), preparation of salivary antigen (recombinant full-length protein, synthetic peptide), malaria detection methodology (light microscopy, RDT, PCR), and entomological vector collection methodology (human landing catch, light traps, and spray catches). Statistical analysis Where there were sufficient data to pool estimates of the same exposure and outcome measures, generalised linear mixed modelling (GLMM) was used to undertake analyses quantifying associations between the exposures of interest and salivary antibody seroprevalence measurements. Models were generalised through use of the logit link function and binomial distribution (statistical notation for HBR model shown below as equation one). Seroprevalence was modelled in binomial form as the number of individuals seropositive to the total sample size. A three-level random effects model with a nested framework was used to account for dependency in the data, with random intercepts for country (level-3) and study (level-2) and level-1 units representing multiple observations per study induced by the study design (i.e. multiple time points, sites, age categories). Additionally, random slopes for entomological and malariometric exposure parameters were included to permit the effect of the exposure of interest (HBR/EIR/malaria prevalence/etc.) to vary across studies. Model structure was determined empirically

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

through likelihood ratio tests (p < 0.05), with the exception of country at the 3rd level which was included in HBR and EIR analyses to estimate country-specific seroprevalence estimates of anti-salivary antibodies. The associations between the various exposures and the different salivary antigens were analysed separately, however estimates of IgG seroprevalence against the recombinant full-length protein (gSG6) and synthetic peptide (gSG6-P1, the one peptide determined in all studies utilising peptides) form of the gSG6 antigen were analysed together, with a fixed term for antigen construct considered for inclusion in the model. Of note, gSG6 peptide 2 (gSG6-P2) was excluded from being analysed with gSG6 and gSG6-P1 estimates, as the two studies that reported anti-gSG6-P2 IgG seroprevalence also reported the seroprevalence of anti-gSG6-P1 IgG, and only one could be included. Potential effect modification of the associations between the exposures of interest and the anti-Anopheles salivary antibody responses was explored was undertaken by estimating interaction terms for DVS (An. gambiae sensu lato (s.l.) only, An. gambiae s.l. and other DVS, or An. gambiae s.l. absent) and for vector collection method (human landing catch or other indirect measures e.g. light traps, spray catches, etc.). For the association between Plasmodium spp. prevalence and gSG6 IgG seropositivity interaction terms for malaria detection methodology (light microscopy or PCR), and malarial species type (P. falciparum only, or P. falciparum and P. vivax) were estimated. Other variables considered for inclusion in adjusted models were study design, participant, salivary antigen construct; however, these variables showed no association with anti-gSG6 IgG and were thus excluded. The natural log of HBR, EIR, malaria prevalence and antimalarial antibody seroprevalence were modelled to account for the non-linear functional form of the association between each measure and the log odds of anti-gSG6 IgG seroprevalence - supported empirically by superior model fit as indicated by Akaike's information criterion (AIC) and Bayesian information criterion (BIC) fit indices. To aid interpretation, odds ratios are presented according to relative per cent increase in the exposures, such that odds ratios reflect relative changes in anti-gSG6 IgG seropositivity for 50% increases HBR and EIR, and 10% increases in malaria prevalence and antimalarial seroprevalence. Additional per cent changes in HBR and EIR are also presented. Empirical Bayes best linear unbiased predictions (BLUPs) were used to estimate the probability of gSG6 IgG seropositivity in the average study and country, which is equivalent to an estimated gSG6 IgG seroprevalence. In order to maximise the number of included studies in our modelling, we predicted anti-gSG6 seroprevalence according to endemicity class, derived by applying established endemicity cut-offs to PfPR₂₋₁₀ estimates [8] extracted from MAP using site year and geolocation (if MAP data unavailable endemicity as stated in study). Intraclass correlation coefficients (ICCs) and 95% reference ranges were estimated for country-, study- and slopespecific heterogeneity (where appropriate) using estimated model variance components.

770 Statistical notation for the generalised linear mixed model used to estimate the association between

771 Anopheles gambiae gSG6 IgG seropositivity and human biting rate (HBR).

The model can be formally written as:

773
$$\operatorname{logit}\{\Pr(y_{ij}=1) \mid x_{ij}, \zeta_{1j}, \zeta_{2i}, \zeta_{3j} \operatorname{log}(HBR)_{ij}\} = \beta_1 + \beta_2 \operatorname{log}(HBR)_{ij} + \zeta_{1j} + \zeta_{2i} + \zeta_{3i} \operatorname{log}(HBR)_{ij},$$
 (1)

774 where

776

778

779

780

781

782

783

784

785

786

787

788

775
$$\zeta_{1j} \sim N(0, \psi_1), \ \zeta_{2i} \sim N(0, \psi_2) \text{ and } \zeta_{3j} \log(HBR)_{ij} \sim N(0, \psi_3),$$
 (2)

Where x_{ij} is the vector of model covariates, β_1 is the model constant and represents the log odds (probability) of

gSG6 IgG seropositivity for a log HBR of zero, β_2 the fixed effect for log HBR for country j and study i, ζ_{1j} the

random-effect (i.e. intercept) for between-country heterogeneity in probability of gSG6 IgG seropositivity, ζ_{2i}

the random-effect (i.e. intercept) for between-study heterogeneity in probability of gSG6 IgG seropositivity, and

 ζ_{3i} the random-effect (i.e. coefficient) for between-study heterogeneity in the effect of log HBR.

Risk of bias in individual studies

For cross-sectional, cohort or intervention studies, selection bias was assessed by reviewing the studies' inclusion and exclusion criteria. Any case-control studies, or studies that presented salivary antibody data stratified by

malaria infection status were included in narrative terms only. Risk of bias was assessed by one reviewer using

the Risk of Bias in Prevalence Studies tool [9]. The risk of bias pertains to the reported seroprevalence estimates

of anti-Anopheles salivary antibodies included in the multilevel modelling.

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

Supplementary File 2. Risk of Bias assessment. Risk of bias was assessed for each study by one independent reviewer using the Risk of Bias in Prevalence Studies tool [9]. This tool comprises 10 items and a summary assessment to assess the external validity (selection and non-response bias) and internal validity (measurement bias) of the study's prevalence estimates. The risk of bias pertains to the reported seroprevalence estimates of anti-Anopheles salivary antibodies included in the multilevel modelling. With regard to external validity, seven of the studies included in the review were performed in specific populations (i.e. children only) that were not representative of the national population and were deemed to be at high risk of selection bias. Only 7 studies included some form of random sampling, and frequently insufficient detail was provided on the sampling frame; as such most studies were included as high risk of selection bias. Furthermore, no studies reported participant response-rate, and as such were indicated as high risk of nonresponse bias. In terms of internal validity, all studies had an acceptable case definition, with the same mode of data collection, a valid instrument and an acceptable prevalence period, so were all deemed to be of low risk. However, 12 studies did not include a denominator, instead only reporting the study sample size and prevalence estimate, and were included as high risk. Overall, due to the specific nature of some of the sample populations for which these prevalence estimates are given (i.e. children only) and as participant non-response rate is not given, we conclude that there is a moderate risk of study bias. According to the Risk of Bias in Prevalence Studies tool [9], this implies that future research is likely to have an impact on our confidence in the prevalence estimates.




Figure S1: Risk of Bias assessment. Red – high risk, orange – moderate risk, green – low risk.

Figure 1 - Supplement 1. Reasons for study exclusion.

Table S1: Reasons for study exclusion

Studies	Reason	References
30	Does not measure anti-salivary antibody responses in individuals/populations	[10-39]
28	Review article	[40-67]
20	Anopheles salivary antigens not assessed	[68-87]
10	Wrong antibody detection methodologies	[88-97]
7	Grey literature	[98-104]
6	Not performed in humans	[105-110]
4	Data already captured by our review from another publication	[111-114]
3	Unable to determine appropriate exposure estimate	[115-117]
3	Not in population with natural exposure	[118-120]
1	Hypothesis study	[121]
1	Pooled sera	[122]
1	Does not provide estimate of seroprevalence/total levels of antibodies against salivary proteins	[123]
1	Study population not representative: Mosquito allergic patients	[124]
1	Study population not representative: Soldiers with transient exposure	[125]

Figure 2 – Supplement 1: Association between gSG6 IgG seropositivity and human biting rate

Table S1: Unadjusted association between gSG6 IgG seropositivity and log Human Biting Rate (HBR).

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log HBR	0.29 (0.08)	0.14, 0.45	< 0.001	
Random part				
$\psi_{\mathtt{1}}{}^{\mathtt{c}}$				1.29
ψ_2				1.55
ψ_3				0.06
$ ho_1{}^{ m d}$				0.21
$ ho_2^{ m e}$				0.47
ℓ				-1489.9
Model fit indices				
AIC				2989.9
BIC				3004.2

Human biting rate (HBR) association: log odds ratio and standard error (SE), 95% confidence interval (95%CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient (ρ)^a and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=132 meta-observations.

 $^{^{}a}$ $\rho = \frac{\psi_{k} + ... + \psi_{nk}}{\psi_{k} + ... + \psi_{nk} + \pi^{2}/3}$, where ψ_{k} through ψ_{nk} are random-effect variance estimates pertaining to each of the respective variance components (see table notes $^{\text{c-e}}$) from the generalised multilevel modelling for a specific ICC estimate.

^b Generalised multilevel modelling estimating the association between log transformed HBR and anti-gSG6 IgG seropositivity with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of HBR.

 $^{c}\psi_{1}, \psi_{2}$ and ψ_{3} represent variances of the random-effects for country, study and effect of HBR respectively.

 ${}^{d}\rho_{1}$ represents conditional ICC for meta-observations from the same country but different study.

 $^{\rm e}\rho_2$ represents conditional ICC for meta-observations from the same country and study with the median HBR

Figure 3 – Supplement 1: Association between gSG6 IgG seropositivity and entomological

inoculation rate

Table S1: Unadjusted association between gSG6 IgG seropositivity log Entomological Inoculation Rate (EIR).

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log EIR	0.15 (0.04)	0.07, 0.23	< 0.001	
Random part				
ψ_1^{c}				1.02
ψ_2				2.15
ψ_3				0.01
$ ho_1{}^{ m d}$				0.16
$ ho_2^{ m e}$				0.49
ℓ				-530.7
Model fit indices				
AIC				1071.3
BIC				1079.5

Entomological inoculation rate (EIR) association: log odds ratio and standard error (SE), 95% confidence interval (95% CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient (ρ)^a and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=38 meta-observations.

- a $\rho = \frac{\psi_{k} + ... + \psi_{nk}}{\psi_{k} + ... + \psi_{nk} + \pi^{2}/3}$, where ψ_{k} through ψ_{nk} are random-effect variance estimates pertaining to each of the respective variance components (see table notes $^{c-e}$) from the generalised multilevel modelling for a specific ICC estimate
- ^b Generalised multilevel modelling estimating the association between log transformed EIR and anti-gSG6 IgG seropositivity with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of EIR.
- $^{\circ}\psi_1, \psi_2$ and ψ_3 represent variances of the random-effects for country, study and effect of EIR respectively.
- $^{d}\rho_{1}$ represents the conditional ICC for meta-observations from the same country but different study .
- $^{\rm e}\rho_2$ represents the conditional ICC for meta-observations from the same country and study with the median EIR

Figure 4 – Supplement 1: Association between gSG6 IgG seropositivity and Human Biting Rate

(HBR), moderated by dominant vector species

848

849

850

851 852

853

854

855

856

857 858

859

860

861

862

863 864

865

Table S1: Association between gSG6 IgG seropositivity and log Human Biting Rate (HBR), moderated by dominant vector species

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log HBR	0.46 (0.11)	0.25, 0.66	< 0.001	
DVS			<0.001*	
An. gambiae s.l. only	Ref.			
An. gambiae s.l. & other DVS	1.00 (0.18)	0.65, 1.25	< 0.001	
Non-An. gambiae s.l.	1.09 (0.68)	-0.24, 2.42	0.109	
log HBR by DVS			<0.001*	
An. gambiae s.l. only	Ref.			
An. gambiae s.l. & other DVS	-0.26 (0.08)	-0.41, -0.11	0.001	
Non-An. gambiae s.l.	-0.38 (0.11)	-0.59, -0.17	< 0.001	
Random part				
${\psi_1}^{ m c}$				0.96
ψ_2				2.32
ψ_3				0.08
$ ho_1{}^{ m d}$				0.14
$ ho_2^{ m e}$				0.51
ℓ				-1488.8
Model fit indices				
AIC				2995.53
BIC				3021.48

Human biting rate (HBR) X dominant vector species (DVS) association: log odds ratio and standard error (SE), 95% confidence interval (95%CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient $(\rho)^a$ and model log likelihood (ℓ) from generalised multilevel modelling. *indicates pvalue from joint Wald test for polytomous variables. This analysis is based upon n=132 meta-observations.

 a $\rho = \frac{\psi_{k} + ... + \psi_{nk}}{\psi_{k} + ... + \psi_{nk} + \pi^{2}/3}$, where ψ_{k} through ψ_{nk} are random-effect variance estimates pertaining to each of the respective variance components (see table notes c-e) from the generalised multilevel modelling for a specific ICC estimate.

^b Generalised multilevel modelling estimating the association between log transformed HBR and anti-gSG6 IgG seropositivity including an interaction term between DVS and log HBR with random-effects for country-specific and study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of HBR. $^{c}\psi_{1}, \psi_{2}$ and ψ_{3} represent variances of the random-effects for country, study and effect of HBR respectively.

 ${}^{\mathrm{d}}
ho_1$ represents the conditional ICC for meta-observations from the same country but different study .

ep, represents the conditional ICC for meta-observations from the same country and study with the median HBR

Figure 5 – Supplement 1. Association between gSG6 IgG seropositivity and malaria prevalence

866

867

868

869

870

871

872

873

874

875 876 877

878

879

Table S1: Unadjusted association between gSG6 IgG seropositivity and log *Plasmodium* spp. prevalence.

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log Plasmodium spp. prevalence	0.46 (0.32)	-0.16, 1.08	0.148	
Random part				
${\psi_1}^{ m c}$				17.21
ψ_2				1.25
$ ho_{\mathtt{1}}^{\hspace{1pt}\mathrm{d}}$				0.85
ℓ				-2597.2
Model fit indices				
AIC				5202.47
BIC				5215.90

Any Plasmodium species infections (including prevalence estimates of P. falciparum only, P. vivax only, both P. falciparum and P. vivax and un-typed infections): log odds ratio and standard error (SE), 95% confidence interval (95% CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient $(\rho)^a$ and model log likelihood (ℓ) from generalised multilevel modelling. This analysis is based upon n=212 meta-observations.

- $\frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the respective variance components (see table notes c-d) from the generalised multilevel modelling for a specific ICC
- ^b Generalised multilevel modelling estimating the association between the log prevalence of any *Plasmodium* spp. infection and anti-gSG6 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6 IgG seroprevalence and study-specific heterogeneity in effect of *Plasmodium* spp. prevalence.
- $^{c}\psi_{1}$ and ψ_{2} represent variances of the random-effects for study and effect of *Plasmodium* spp. prevalence 880 881 respectively.
- 882 ${}^{d}\rho_{1}$ represents the conditional ICC for meta-observations from the same study and with the median *Plasmodium* 883 spp. prevalence.

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

Supplementary File 3. Association between gSG6 IgG seropositivity and antimalarial antibody seroprevalence Antibodies against *P. falciparum* pre-erythrocytic stage antigens The pooled analysis of 159 meta-observations from eight studies showed that a 10% relative increase in PfCSP IgG seropositivity was associated with a 11% (OR: 1.11; 95% CI: 1.02-1.21%, p=0.013) increase in odds of antigSG6 IgG seropositivity [126-133]. Furthermore we observed that gSG6 IgG levels increased with increasing PfCSP IgG seroprevalence in four studies [127-129, 133], with another study contributing only a single estimate [132]. Antibodies against P. falciparum blood stage antigens Furthermore, we observed a 10% relative increase PfAMA1 IgG seroprevalence was associated with a 13% (OR: 1.13; 95%CI: 1.12-1.15%; p<0.001) increase in odds of gSG6 IgG seropositivity, based upon 62 metaobservations from eight studies [128-135]. A similar association was observed for PfMSP1₁₉ IgG, with 10% relative increase in seroprevalence associated with 13% (OR: 1.13; 95% CI: 1.03-1.25%; p=0.014) increase in odds of gSG6 IgG seropositivity. This association was derived from 163 meta-observations from ten studies [127-130, 132-136]. Analysis of 47 meta-observations from three studies indicated that a 10% relative increase in PfMSP2 IgG seroprevalence was associated with a 5% (OR: 1.05; 95%CI: 1.03-1.07%; p<0.001) increase in odds of gSG6 IgG seropositivity [130, 133, 135]. While 17 meta-observations from two studies showed a 10% relative increase in PfMSP3 IgG seroprevalence was associated with a 14% (OR: 1.14; 95%CI: 1.13-1.16%; p<0.001) increase in odds of gSG6 IgG seropositivity [132, 135]. The pooled analysis of 128 meta-observations from five studies showed that a 10% relative increase in PfGLURP IgG seroprevalence was associated with a 17% (OR: 1.17; 95% CI: 1.14-1.19%; p<0.001) increase in odds of gSG6 IgG seropositivity [126-130]. And 18 meta-observations from five studies indicated that 10% relative increase in P. falciparum schizont extract IgG seropositivity was associated with a 27% (OR: 1.27; 95%CI: 0.61-2.65%; *p*=0.523) increase in odds of gSG6 IgG seropositivity [128-130, 134, 137]. We observed that increasing seroprevalence of IgG antibodies against PfAMA1 saw increased levels of anti-gSG6 IgG in three studies [128, 129, 134], but no association in another [133]. The levels of gSG6 IgG increased with increasing PfMSP1₁₉ IgG seroprevalence in three studies [128, 134, 136], but showed no association in three other studies [127, 129, 133]. No association between gSG6 IgG levels and MSP2 IgG seroprevalence was observed in one study [133]. PfGLURP IgG seroprevalence and gSG6 IgG antibody levels were reported in three studies,

with one study reporting increased levels [128], one study reporting no association [127], and one study reporting decreased levels of anti-gSG6 IgG with increasing anti-PfGLURP seroprevalence [129]. One study showed increasing gSG6 IgG levels with increasing *P. falciparum* schizont extract IgG, while three other studies showed no association [128, 129, 137]. Of note, one study provided a single seroprevalence estimate of antibodies against PfAMA1, PfMSP1₁₉ and PfMSP3 so no relationships can be drawn [132].

Antibodies against *P. vivax* antigens

In pooled analyses of 115 meta-observations from two studies [127, 134], we observed that 10% relative increase in the seroprevalence of PvAMA1 was associated with a 20% (OR: 1.20; 95%CI: 1.19-1.22%; *p*<0.001) increase in the odds of anti-gSG6 IgG seropositivity. Furthermore, in 103 meta-observations from two studies [127, 134], 10% relative increase in PvMSP1₁₉ IgG seroprevalence was associated with a 13% (OR: 1.13; 95%CI: 1.12-1.13%; *p*<0.001) increase in the odds of anti-gSG6 IgG seropositivity. However, neither study showed an

association between the levels of gSG6 IgG and the seroprevalence of PvAMA1 and PvMSP1₁₉ IgG [127, 134].

Table S1: Associations between anti-gSG6 IgG seropositivity and log of antimalarial antibody seroprevalence.

Exposure	Log Odds Ratio (SE)	95%CI	p- value	Meta-N	Studies	References
Pre-erythrocytic antigens						
log PfCSP IgG Seroprevalence (%)	1.13 (0.45)	0.24, 2.01	0.013	159	8	[126-133]
Blood stage antigens						
log PfAMA1 IgG Seroprevalence (%) ^a	1.30 (0.07)	1.17, 1.44	< 0.001	62	8	[128-135]
log PfMSP1 ₁₉ IgG Seroprevalence (%)	1.31 (0.53)	0.27, 2.36	0.014	163	10	[127-130, 132-136]
log PfMSP2 IgG Seroprevalence (%)	0.50 (0.11)	0.27, 0.72	< 0.001	47	3	[130, 133, 135]
log PfMSP3 IgG Seroprevalence (%) ^a	1.41 (0.09)	1.24, 1.58	< 0.001	17	2	[132, 135]
log PfGLURP IgG Seroprevalence (%)	1.61 (0.12)	1.37, 1.85	< 0.001	128	5	[126-130]
log PfSchizont Extract IgG Seroprevalence (%)	2.51 (3.93)	-5.20, 10.22	0.523	18	5	[128-130, 134, 137]
log PvAMA1 IgG Seroprevalence (%)	1.95 (0.08)	1.79, 2.11	< 0.001	115	2	[127, 134]
log PvMSP1 ₁₉ IgG Seroprevalence (%)	1.25 (0.04)	1.17, 1.32	< 0.001	103	2	[127, 134]

Effects for each exposure represent separate generalised multilevel modelling analyses estimating the association between the log of the seroprevalence of antimalarial antibodies and the seroprevalence of anti-gSG6 IgG, with the inclusion of a random intercept for study-specific heterogeneity and a random coefficient to allow the effect of the antimalarial antigen to vary across studies. Table shows log odds ratio and standard error (SE), 95% confidence interval (95%CI) and p-value, number of meta-observations (Meta-N) and studies, with associated references. Random effects not shown.

^a Studies did not include a random coefficient (*i.e.* slope); as empirical support was not shown.

932

933

934

935

936

937

938

939

Supplementary File 4. Country and study-specific predicted probability of gSG6 IgG seropositivity. In order to obtain estimates of gSG6 IgG seroprevalence for each country and study, an intercept only three-level random effects logistic regression was fitted to 301 meta-observations from 22 studies. The predicted probability of gSG6 IgG seropositivity was calculated at the country-level (Figure S1), indicating that the seroprevalence was lowest in the Pacific Region (Vanuatu (31%) and Solomon Islands (32%)) and highest in Benin (72%) and Burkina Faso (65%). Furthermore, the predicted probability of gSG6 IgG seropositivity was calculated at the study-level (Figure S2) indicating that the seroprevalence was lowest in Ambrosino et al. [126] (13%) and highest in Drame et al. [138] (91%).




Figure S1: Predicted gSG6 IgG seroprevalence by country. Predicted probabilities of gSG6 IgG seropositivity including country-specific random effects with 95% confidence intervals. Estimated from intercept-only three-level random-effects logistic regression to account for the hierarchical nature of the data, with an anti-gSG6 IgG meta-observation nested within study nested within country. Based upon 301 meta-observations from 22 studies.




Figure S2: Predicted gSG6 IgG seroprevalence by study. Predicted probabilities of gSG6 IgG seropositivity including study-specific random effects with 95% confidence intervals. Estimated from intercept-only three-level random-effects logistic regression to account for the hierarchical nature of the data, with an anti-gSG6 IgG meta-observation nested within study nested within country. Based upon 301 meta-observations from 22 studies.

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

Supplementary File 5. Association between alternative salivary biomarkers and exposures of interest. Our systematic review identified a paucity of studies that assessed the relationship between our exposures of interest and most alternate Anopheles salivary biomarkers (that is non-An. gambiae gSG6 IgG), thus preventing the estimation of a pooled association. The exceptions being that we observed that a 50% relative increase in HBR was associated with a 7% increase (OR: 1.07; 95%CI: 1.01-1.13%; p=0.017) in odds of anti-An. funestus fSG6 IgG seropositivity (six meta-observations from two studies [139, 140]; Table 1), as well as a 42% (OR: 1.42; 95% CI: 1.39-1.46%; p<0.001) and 21% (OR: 1.21; 95% CI: 1.19-1.23%; p<0.001) increase in odds of anti-gSG6-P2 IgG seropositivity associated with 10% relative increase in seroprevalence of PfCSP and PfGLURP IgG, respectively (115 and 116 meta-observations from two studies respectively [126, 127], Table 2-3). The associations between exposures of interest and the additional salivary biomarkers are further discussed in narrative terms in below. **Human biting rate** In addition to the increased odds of An. funestus fSG6 seropositivity with increasing HBR, the majority of studies reported a positive association between HBR and the seroprevalence and levels of anti-gSG6-P1 IgM [138], the levels of gSG6-P2 IgG [141], the seroprevalence and levels of anti-cE5 IgG [142], the levels of anti-fSG6 IgG [139, 140], the seroprevalence and levels of anti-f5'nuc IgG [139] and the median levels of anti-An. gambiae salivary gland extracts (SGE) SGE IgG and IgG4 [143-145]. One study reported similar median levels of antigSG6 IgG1 across populations and time points, whilst reporting that anti-gSG6 IgG4 titre increased with increasing HBR in one of the populations, but not in the other [146]. Similarly, there was no consistent association between HBR and the levels of anti-cE5 IgG [147], levels of anti-An. gambiae SGE IgE [145] and the seroprevalence and levels of anti-g5'nuc IgG [139]. **Entomological inoculation rate** Ali et al. [139] reported higher seroprevalence and levels anti-fSG6 IgG and anti-f5'nuc IgG with increasing EIR, while anti-g5'nuc IgG seroprevalence and levels were not associated with EIR. An additional study reported gSG6-P2 IgG seroprevalence estimates of 0% for three sites, irrespective of EIR [126].

Malaria prevalence

Two studies showed that increased *Plasmodium* spp. prevalence was associated with higher median levels of anti-*An. gambiae* SGE IgG [143, 148], while another study showed different anti-*An. gambiae* SGE IgG levels for very similar prevalence of malaria and slightly lower levels of anti-*An. gambiae* SGE IgE and IgG4 for the time point with greater malaria prevalence [145]. Kerkhof *et al.* [127] showed increasing levels of anti-gSG6-P2 IgG for higher prevalence of any *Plasmodium* spp. infection, while Londono-Renteria *et al.* [149] showed lower levels of IgG antibodies against TRANS-P1, TRANS-P2, PEROX-P1, PEROX-P2 and PEROX-P3 in the site with higher PCR confirmed malaria prevalence. Additionally, several case-controlled studies, and two cross-sectional study, reported median antibody levels stratified by malaria infection status. These studies show higher levels of anti-*An. darlingi* SGE IgG [150], anti-*An. gambiae* SGE IgG [144], anti-*An. dirus* SGE IgG and IgM [151], and IgG antibodies against SGEs of two Colombian strains of *An. albimanus* in *Plasmodium* spp. infected individuals, compared to non-infected [152]. While Montiel *et al.* [152] observed no association between anti-*An. darlingi* SGE IgG levels and infection status.

Antimalarial antibody seroprevalence

Our multilevel modelling indicated that there were 42% (OR: 1.42; 95%CI: 1.39-1.46%; p<0.001) and 21% (OR: 1.21; 95%CI: 1.19-1.23%; p<0.001) increase in odds of anti-gSG6-P2 IgG seropositivity associated with a 10% relative increase in the seroprevalence of PfCSP and PfGLURP IgG, respectively [126, 127]. However, we observed weak positive associations between the levels of IgG antibodies against gSG6-P2 peptide and the seroprevalence of IgG antibodies against PfMSP1₁₉, PfGLURP and PvMSP1₁₉, but no association with PfCSP or PvAMA1 [127].

Table S1: Association between fSG6 IgG seropositivity and human biting rate

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log HBR	0.17 (0.07)	0.03, 0.31	0.017	
Random part				
${\psi_1}^{ m c}$				0.47
$ ho_1{}^{ m d}$				0.13

Association between human biting rate (HBR) and fSG6 IgG: log odds ratio and standard error (SE), 95% confidence interval (95%CI), p-value, random-effect components (RE): variances (ψ), conditional intraclass correlation coefficient $(\rho)^a$ and model log likelihood (ℓ) from generalised multilevel modelling. This analysis is based upon n=6 meta-observations.

 $\frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3}$, where ψ_k through ψ_{nk} are random-effect variance estimates pertaining to each of the respective variance components (see table notes ^{c-d}) from the mixed–effect generalised (logit) linear mixed models for a specific ICC estimate.

^b Generalised multilevel modelling estimating the association between anti-An. funestus fSG6 IgG seropositivity and log transformed HBR with random-effects for study-specific heterogeneity in fSG6 IgG seropositivity.

 $^{\rm c}\psi_1$ represents variance of the random-effect for study.

994

995

996

997

998

999 1000

1001

1002

1003

1004

1011

1012 1013

1014

1015

1016

1023

1024

 ${}^{\mathrm{d}}\rho_1$ represents conditional ICC for meta-observations from the same study.

Table S2: Association between gSG6-P2 IgG seropositivity and log PfCSP IgG seroprevalence

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log PfCSP IgG Seroprevalence	3.70 (0.12)	3.45, 3.94	< 0.001	
Random part				
$\psi_{\mathtt{1}}{}^{\mathtt{c}}$				25.2
$ ho_{\mathtt{1}}{}^{\mathrm{d}}$				0.88

Association between log PfCSP seroprevalence and gSG6-P2 IgG: log odds ratio and standard error (SE), 95% confidence interval (95% CI), p-value, random-effect variances (ψ), conditional intraclass correlation coefficient (ρ)^a and model log likelihood (ℓ) from generalised multilevel modelling.^b This analysis is based upon n=115 meta-observations.

- a $ho = \frac{\psi_{k} + ... + \psi_{nk}}{\psi_{k} + ... + \psi_{nk} + \pi^{2}/3}$, where ψ_{k} through ψ_{nk} are random-effect (RE) variance estimates pertaining to each of the
- 1017 respective variance components (see table notes ^{c-d}) from the mixed–effect generalised (logit) linear mixed models 1018 for a specific ICC estimate.
- ^b Generalised multilevel modelling estimating the association between log PfCSP seroprevalence and anti-gSG6-1019 1020 P2 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6-P2 IgG seropositivity.
- 1021 $^{\rm c}\psi_1$ represents variance of the random-effect for study.
- ${}^{\mathrm{d}}\rho_1$ represents conditional ICC for meta-observations from the same study. 1022

Table S3: Association between gSG6-P2 IgG seropositivity and log PfGLURP IgG seroprevalence

Variable	Log Odds Ratio (SE)	95% CI	p-value	RE
Fixed part				
log PfGLURP IgG Seroprevalence	2.01 (0.09)	1.85, 2.18	< 0.001	
Random part				
$\psi_1{}^{\mathrm{c}}$				24.3
$ ho_{\mathtt{1}}{}^{\mathrm{d}}$				0.88

Association between log PfGLURP seroprevalence and gSG6-P2 IgG: log odds ratio and standard error (SE), 95% confidence interval (95%CI), p-value, random-effect variances (ψ), conditional intraclass correlation coefficient (p)^a and model log likelihood (l) from generalised multilevel modelling. This analysis is based upon n=116 meta-observations.

- $^{\text{a}}\,\rho = \frac{\psi_k + ... + \psi_{nk}}{\psi_k + ... + \psi_{nk} + \pi^2/3} \,\,\text{, where}\,\,\psi_k \,\,\text{through}\,\,\psi_{nk} \,\,\text{are random-effect (RE) variance estimates pertaining to each of the}$ respective variance components (see table notes ^{c-d}) from the mixed–effect generalised (logit) linear mixed models for a specific ICC estimate.
- b Generalised multilevel modelling estimating the association between log PfGLURP seroprevalence and anti-1033 1034 gSG6-P2 IgG seropositivity with random-effects for study-specific heterogeneity in gSG6-P2 IgG seropositivity. 1035 $^{c}\psi_{1}$ represents variance of the random-effect for study.
- ${}^{\mathrm{d}}\rho_1$ represents conditional ICC for meta-observations from the same study. 1036

1025

1026

1027

1028

1029

1030 1031

Supplementary References

- 1038 1. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA,
- Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of
- 1040 Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. Epub 2000/05/02. doi: 1041 10.1001/jama.283.15.2008. PubMed PMID: 10789670.
- 1042 2. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 1044 10.1371/journal.pmed.1000097.
- 1045 3. Yamba EI, Tompkins AM, Fink AH, Ermert V, Djouda A, Amekudzi LK, Briët OJT. Monthly entomological inoculation rates for studying malaria transmission seasonality in Africa. PANGAEA; 2018.
- The Malaria Atlas Project [Internet]. 2017. Available from: https://malariaatlas.org/.
- 1048 5. Cutts JC, Agius PA, Zaw L, Powell R, Moore K, Draper B, Simpson JA, Fowkes FJI. Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. BMC Med. 2020;18(1):14. Epub 2020/01/17. doi: 10.1186/s12916-019-1467-6. PubMed PMID: 31941488; PubMed Central
- 1051 PMCID: PMCPMC6964062.
- 1052 6. Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. Immunological markers of 1053 *Plasmodium vivax* exposure and immunity: a systematic review and meta-analysis. BMC Med. 2014;12:150. Epub 1054 2014/09/10. doi: 10.1186/s12916-014-0150-1. PubMed PMID: 25199532; PubMed Central PMCID:
- 1055 PMCPMC4172944.
- 7. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: A systematic review and meta-analysis. PLoS Med. 2010;7(1):e1000218-e. doi: 10.1371/journal.pmed.1000218. PubMed PMID: 20098724.
- 8. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11. Epub 2015/09/16. doi: 10.1038/nature15535. PubMed PMID: 26375008.
- Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934-9. doi: 10.1016/j.jclinepi.2011.11.014.
- 10. Alvarenga PH, Francischetti IMB, Calvo E, Sa-Nunes A, Ribeiro JMC, Andersen JF. The Function and Three-Dimensional Structure of a Thromboxane A(2)/Cysteinyl Leukotriene-Binding Protein from the Saliva of a Mosquito Vector of the Malaria Parasite. PLoS Biol. 2010;8(11). doi: 10.1371/journal.pbio.1000547. PubMed PMID: WOS:000284762300019.
- 1071 11. Arcà B, Lombardo F, Struchiner CJ, Ribeiro JM. Anopheline salivary protein genes and gene families: an evolutionary overview after the whole genome sequence of sixteen *Anopheles* species. BMC Genomics. 2017;18(1):153. doi: 10.1186/s12864-017-3579-8.
- 1074 12. Arcà B, Lombardo F, Valenzuela JG, Francischetti IMB, Marinotti O, Coluzzi M, Ribeiro JMC. An updated catalogue of salivary gland transcripts in the adult female mosquito, Anopheles gambiae. J Exp Biol. 2005;208(20):3971-86. doi: 10.1242/jeb.01849.
- 1077 13. Calvo E, Dao A, Pham VM, Ribeiro JM. An insight into the sialome of Anopheles funestus reveals an emerging pattern in anopheline salivary protein families. Insect Biochem Mol Biol. 2007;37(2):164-75. doi: 10.1016/j.ibmb.2006.11.005.
- 1080 14. Calvo E, Mans BJ, Andersen JF, Ribeiro JMC. Function and evolution of a mosquito salivary protein family. J Biol Chem. 2006;281(4):1935-42. doi: 10.1074/jbc.M510359200.
- 1082 15. Choumet V, Carmi-Leroy A, Laurent C, Lenormand P, Rousselle JC, Namane A, Roth C, Brey PT. The salivary glands and saliva of Anopheles gambiae as an essential step in the Plasmodium life cycle: A global proteomic study. Proteomics. 2007;7(18):3384-94. doi: 10.1002/pmic.200700334.
- 1085 16. Das S, Radtke A, Choi Y, Mendes AM, Valenzuela JG, Dimopoulos G. Transcriptomic and functional analysis of the Anopheles gambiae salivary gland in relation to blood feeding. BMC Genomics. 2010;11(1). doi: 10.1186/1471-2164-11-566.
- 1088 17. Di Gaetano S, Del Gatto A, Pirone L, Comegna D, Zaccaro L, Saviano M, Arca B, Capasso D, Pedone E. A selective alpha(v)beta(5) integrin antagonist hidden into the anophelin family protein cE5 from the malaria
- 1090 vector Anopheles gambiae. Peptide Science. 2018;110(5). doi: 10.1002/pep2.24054. PubMed PMID:
- 1091 WOS:000450664700016.

- 1092 18. Dixit R, Sharma A, Mourya DT, Kamaraju R, Patole MS, Shouche YS. Salivary gland transcriptome analysis during Plasmodium infection in malaria vector Anopheles stephensi. Int J Infect Dis. 2009;13(5):636-46.
- 1094 doi: 10.1016/j.ijid.2008.07.027.
- 1095 19. Francischetti IM, Ma D, Andersen JF, Ribeiro JM. Evidence for a lectin specific for sulfated glycans in
- the salivary gland of the malaria vector, Anopheles gambiae. PLoS One. 2014;9(9):e107295. doi:
- 1097 10.1371/journal.pone.0107295.
- 1098 20. Francischetti IM, Valenzuela JG, Pham VM, Garfield MK, Ribeiro JM. Toward a catalog for the transcripts and proteins (sialome) from the salivary gland of the malaria vector Anopheles gambiae. J Exp Biol.
- 1100 2002;205(Pt 16):2429-51.
- 1101 21. Ghosh AK, Devenport M, Jethwaney D, Kalume DE, Pandey A, Anderson VE, Sultan AA, Kumar N,
- Jacobs-Lorena M. Malaria parasite invasion of the mosquito salivary gland requires interaction between the
- Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog. 2009;5(1):e1000265. doi:
- 1104 10.1371/journal.ppat.1000265.
- 1105 22. Isaacs AT, Mawejje HD, Tomlinson S, Rigden DJ, Donnelly MJ. Genome-wide transcriptional analyses
- in Anopheles mosquitoes reveal an unexpected association between salivary gland gene expression and insecticide
- 1107 resistance. BMC Genomics. 2018;19(1). doi: 10.1186/s12864-018-4605-1.
- 1108 23. Jariyapan N, Baimai V, Poovorawan Y, Roytrakul S, Saeung A, Thongsahuan S, Suwannamit S, Otsuka
- 1109 Y, Choochote W. Analysis of female salivary gland proteins of the Anopheles barbirostris complex (Diptera:
- 1110 Culicidae) in Thailand. Parasitol Res. 2010;107(3):509-16. doi: 10.1007/s00436-010-1883-1.
- 1111 24. Jariyapan N, Choochote W, Jitpakdi A, Harnnoi T, Siriyasatein P, Wilkinson MC, Bates PA. A glycine-
- and glutamate-rich protein is female salivary gland-specific and abundant in the malaria vector Anopheles dirus
- 1113 B (Diptera: Culicidae). J Med Entomol. 2006;43(5):867-74. doi: 10.1603/0022-
- 1114 2585(2006)43[867:AGAGPI]2.0.CO;2.
- 1115 25. Jariyapan N, Roytrakul S, Paemanee A, Junkum A, Saeung A, Thongsahuan S, Sor-suwan S,
- Phattanawiboon B, Poovorawan Y, Choochote W. Proteomic analysis of salivary glands of female Anopheles
- barbirostris species A2 (Diptera: Culicidae) by two-dimensional gel electrophoresis and mass spectrometry.
- 1118 Parasitol Res. 2012;111(3):1239-49. doi: 10.1007/s00436-012-2958-y.
- 1119 26. Kamiya T, Greischar MA, Mideo N. Epidemiological consequences of immune sensitisation by pre-
- exposure to vector saliva. PLoS Negl Trop Dis. 2017;11(10). doi: 10.1371/journal.pntd.0005956.
- 1121 27. Khaireh BA, Briolant S, Pascual A, Mokrane M, MacHault V, Travaillé C, Khaireh MA, Farah IH, Ali
- HM, Abdi AIA, Ayeh SN, Darar HY, Ollivier L, Waiss MK, Bogreau H, Rogier C, Pradines B. Plasmodium vivax and Plasmodium falciparum infections in the Republic of Djibouti: Evaluation of their prevalence and potential
- 1124 determinants. Malar J. 2012;11. doi: 10.1186/1475-2875-11-395.
- 1125 28. Korochkina S, Barreau C, Pradel G, Jeffery E, Li J, Natarajan R, Shabanowitz J, Hunt D, Frevert U,
- Vernick KD. A mosquito-specific protein family includes candidate receptors for malaria sporozoite invasion of salivary glands. Cell Microbiol. 2006;8(1):163-75. doi: 10.1111/j.1462-5822.2005.00611.x.
- 1128 29. Lombardo F, Ronca R, Rizzo C, Mestres-Simòn M, Lanfrancotti A, Currà C, Fiorentino G, Bourgouin
- 1129 C, Ribeiro JM, Petrarca V, Ponzi M, Coluzzi M, Arcà B. The Anopheles gambiae salivary protein gSG6: an
- anopheline-specific protein with a blood-feeding role. Insect Biochem Mol Biol. 2009;39(7):457-66. doi:
- 1131 10.1016/j.ibmb.2009.04.006.
- 1132 30. Pandey RK, Bhatt TK, Prajapati VK. Novel Immunoinformatics Approaches to Design Multi-epitope
- Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein. Sci Rep. 2018;8(1):1125. doi:
- 1134 10.1038/s41598-018-19456-1.
- 1135 31. Pedro PM, Sallum MAM. Spatial expansion and population structure of the neotropical malaria vector,
- 1136 Anopheles darlingi (Diptera: Culicidae). Biol J Linn Soc. 2009;97(4):854-66. doi: 10.1111/j.1095-
- 1137 8312.2009.01226.x.
- 1138 32. Phattanawiboon B, Jariyapan N, Mano C, Roytrakul S, Paemanee A, Sor-Suwan S, Sriwichai P, Saeung
- A, Bates PA. Salivary Gland Proteome during Adult Development and after Blood Feeding of Female Anopheles
- dissidens Mosquitoes (Diptera: Culicidae). PLoS One. 11(9):e0163810. doi: 10.1371/journal.pone.0163810.
- 1141 33. Pirone L, Ripoll-Rozada J, Leone M, Ronca R, Lombardo F, Fiorentino G, Andersen JF, Pereira PJB,
- 1142 Arcà B, Pedone E. Functional analyses yield detailed insight into the mechanism of thrombin inhibition by the
- antihemostatic salivary protein cE5 from Anopheles gambiae. J Biol Chem. 2017;292(30):12632-42. doi:
- 1144 10.1074/jbc.M117.788042. PubMed PMID: PDB/3U69PDB/4E05PDB/5NHU.
- 1145 34. Rawal R, Vijay S, Kadian K, Singh J, Pande V, Sharma A. Towards a Proteomic Catalogue and
- 1146 Differential Annotation of Salivary Gland Proteins in Blood Fed Malaria Vector Anopheles culicifacies by Mass
- 1147 Spectrometry. PLoS One. 2016;11(9):e0161870. doi: 10.1371/journal.pone.0161870.

- 1148 35. Ronca R, Kotsyfakis M, Lombardo F, Rizzo C, Currà C, Ponzi M, Fiorentino G, Ribeiro JM, Arcà B.
- The Anopheles gambiae cE5, a tight- and fast-binding thrombin inhibitor with post-transcriptionally regulated
- salivary-restricted expression. Insect Biochem Mol Biol. 2012;42(9):610-20. doi: 10.1016/j.ibmb.2012.04.008.
- 1151 36. Sarr JB, Remoue F, Samb B, Dia I, Guindo S, Sow C, Maiga S, Tine S, Thiam C, Schacht AM, Simondon
- 1152 F, Konate L, Riveau G. Evaluation of antibody response to Plasmodium falciparum in children according to
- exposure of Anopheles gambiae s.l or Anopheles funestus vectors. Malar J. 2007;6. doi: 10.1186/1475-2875-6-1154 117.
- 1155 37. Scarpassa VM, Debat HJ, Alencar RB, Saraiva JF, Calvo E, Arcà B, Ribeiro JMC. An insight into the
- sialotranscriptome and virome of Amazonian anophelines. BMC Genomics. 2019;20(1):166. doi:
- 1157 10.1186/s12864-019-5545-0.
- 1158 38. Wells MB, Andrew DJ. Salivary gland cellular architecture in the Asian malaria vector mosquito
- 1159 Anopheles stephensi. Parasit Vectors. 2015;8:617-.
- 1160 39. Zocevic A, Carmi-Leroy A, Sautereau J, d'Alayer J, Lenormand P, Rousselle JC, Namane A, Choumet
- 1161 V. New markers in Anopheles gambiae salivary glands after Plasmodium berghei infection. Vector Borne
- Zoonotic Dis. 2013;13(2):119-27. doi: 10.1089/vbz.2012.0964.
- The mal ERARCPoTfME. malERA: An updated research agenda for diagnostics, drugs, vaccines, and
- 1164 vector control in malaria elimination and eradication. PLoS Med. 2017;14(11). doi:
- 1165 10.1371/journal.pmed.1002455.
- 1166 41. The mal ERARCPoBS, Enabling T. malERA: An updated research agenda for basic science and enabling
- 1167 technologies in malaria elimination and eradication. PLoS Med. 2017;14(11). doi:
- 1168 10.1371/journal.pmed.1002451.
- 1169 42. The mal ERARCPoCtR, Measuring T. malERA: An updated research agenda for characterising the
- 1170 reservoir and measuring transmission in malaria elimination and eradication. PLoS Med. 2017;14(11). doi:
- 1171 10.1371/journal.pmed.1002452.
- 1172 43. Andrade BB, Barral-Netto M. Biomarkers for susceptibility to infection and disease severity in human
- 1173 malaria. Mem Inst Oswaldo Cruz. 2011;106:70-8. doi: 10.1590/s0074-02762011000900009. PubMed PMID:
- 1174 WOS:000294440600009.
- 1175 44. Andrade BB, Teixeira CR, Barral A, Barral-Netto M. Haematophagous arthropod saliva and host defense
- 1176 system: A tale of tear and blood. An Acad Bras Cienc. 2005;77(4):665-93. doi: 10.1590/S0001-
- 1177 37652005000400008.
- 1178 45. Billingsley PF, Baird J, Mitchell JA, Drakeley C. Immune interactions between mosquitoes and their
- 1179 hosts. Parasite Immunol. 2006;28(4):143-53. doi: 10.1111/j.1365-3024.2006.00805.x. PubMed PMID:
- 1180 WOS:000236064500004.
- 1181 46. Cantillo JF, Fernández-Caldas E, Puerta L. Immunological aspects of the immune response induced by
- mosquito allergens. Int Arch Allergy Immunol. 2014;165(4):271-82. doi: 10.1159/000371349.
- 1183 47. Coutinho-Abreu IV, Guimaraes-Costa AB, Valenzuela JG. Impact of insect salivary proteins in blood
- feeding, host immunity, disease, and in the development of biomarkers for vector exposure. Curr Opin Insect.
- 1185 2015;10:98-103. doi: 10.1016/j.cois.2015.04.014. PubMed PMID: WOS:000369017500015.
- 1186 48. Domingos A, Pinheiro-Silva R, Couto J, do Rosário V, de la Fuente J. The Anopheles gambiae
- $1187 \qquad \text{transcriptome} \text{a turning point for malaria control. Insect Mol Biol.} \ 2017; 26(2): 140-51. \ \text{doi: } 10.1111/\text{imb.} 12289.$
- 1188 49. Doucoure S, Cornelie S, Drame PM, Marie A, Ndille EE, Mathieu-Daudé F, Mouchet F, Poinsignon A,
- Remoue F. Biomarkers of vector bites: Arthropod immunogenic salivary proteins in vector-borne diseases control.
- In: Preedy VR, Patel VB, editors. General Methods in Biomarker Research and their Applications. 2-22015. p. 1191 1177-205.
- 1192 50. Doucoure S, Drame PM. Salivary Biomarkers in the Control of Mosquito-Borne Diseases. Insects.
- 1193 2015;6(4):961-76. doi: 10.3390/insects6040961.
- 1194 51. Drame PM, Poinsignon A, Marie A, Noukpo H, Doucoure S, Cornelie S, Remoue F, Manguin S. New
- Salivary Biomarkers of Human Exposure to Malaria Vector Bites. In: Manguin S, editor. Anopheles mosquitoes:
- New insights into malaria vectors2013. p. 755-95.
- 1197 52. Fontaine A, Diouf I, Bakkali N, Missé D, Pagès F, Fusai T, Rogier C, Almeras L. Implication of
- haematophagous arthropod salivary proteins in host-vector interactions. Parasit Vectors. 2011;4(1). doi:
- 1199 10.1186/1756-3305-4-187.
- 1200 53. Foy BD, Killeen GF, Magalhaes T, Beier JC. Immunological targeting of critical insect antigens. Am
- 1201 Entomol. 2002;48(3):150-62. doi: 10.1093/ae/48.3.150.
- 1202 54. Gillespie RD, Mbow ML, Titus RG. The immunomodulatory factors of bloodfeeding arthropod saliva.
- 1203 Parasite Immunol. 2000;22(7):319-31. doi: 10.1046/j.1365-3024.2000.00309.x.

- 1204 55. Hopp CS, Sinnis P. The innate and adaptive response to mosquito saliva and Plasmodium sporozoites in
- 1205 the skin. Ann N Y Acad Sci. 2015;1342:37-43. doi: 10.1111/nyas.12661. PubMed PMID: 1206 WOS:000353102900005.
- 1207 56. Hugo RLE, Birrell GW. Proteomics of Anopheles Vectors of Malaria. Trends Parasitol.
- 1208 2018;34(11):961-81. doi: 10.1016/j.pt.2018.08.009.
- 1209 57. Leitner WW, Denis ACS, Wali T. Immunological consequences of arthropod vector-derived salivary
- 1210 factors. Eur J Immunol. 2011;41(12):3396-400. doi: 10.1002/eji.201190075.
- 1211 58. Lombardo F, Lanfrancotti A, Mestres-Simón M, Rizzo C, Coluzzi M, Arcà B. At the interface between
- 1212 parasite and host: The salivary glands of the African malaria vector Anopheles gambiae. Parassitologia.
- 1213 2006;48(4):573-80.
- 1214 59. Mathema VB, Na-Bangchang K. A brief review on biomarkers and proteomic approach for malaria
- 1215 research. Asian Pac J Trop Med. 2015;8(4):253-62. doi: 10.1016/S1995-7645(14)60327-8.
- 1216 60. Peng Z, Estelle F, Simons R. Mosquito allergy and mosquito salivary allergens. Protein Peptide Lett.
- 1217 2007;14(10):975-81. doi: 10.2174/092986607782541088. PubMed PMID: WOS:000253577700007.
- 1218 61. Ribeiro JMC, Francischetti IMB. Role of Arthropod Saliva in Blood Feeding: Sialome and Post-Sialome
- Perspectives. Annu Rev Entomol. 2003;48:73-88. doi: 10.1146/annurev.ento.48.060402.102812.
- 1220 62. Sagna A, Poinsignon A, Remoue F, Wikel SK, Aksoy S, Dimopoulos G. Epidemiological Applications
- of Assessing Mosquito Exposure in a Malaria-Endemic Area. In: Wikel SK, Dimopoulos G, Aksoy S, editors.
- Arthropod Vector: Controller of Disease Transmission, Volume 2: Vector Saliva-Host Pathogen Interactions 2017. p. 209-29.
- 1224 63. Sá-Nunes A, De Oliveira CJF. Sialogenins and immunomodulators derived from blood feeding parasites.
- 1225 In: Kini R, Clemetson K, Markland F, McLane M, Morita T, editors. Toxins and Hemostasis 2011. p. 131-52.
- 1226 64. Miot HA, Lima HC. Allergy to Hematophagous Arthropods Bites. Current Dermatology Reports. 1227 2014;3(1):6-12.
- 1228 65. Peng Z, Simons FER. Mosquito allergy: immune mechanisms and recombinant salivary allergens. Int 1229 Arch Allergy Appl Immunol. 2004;133(2):198-209.
- 1230 66. Pingen M, Schmid MA, Harris E, McKimmie CS. Mosquito biting modulates skin response to virus
- infection. Trends Parasitol. 2017;33(8):645-57.

 Sinden RE, Blagborough AM, Churcher T, Ramakrishnan C, Biswas S, Delves MJ. The design and
- interpretation of laboratory assays measuring mosquito transmission of Plasmodium. Trends Parasitol.
- 1234 2012;28(11):457-65.
- 1235 68. Abonuusum A, Owusu-Daako K, Tannich E, May J, Garms R, Kruppa T. Malaria transmission in two
- rural communities in the forest zone of Ghana. Parasitol Res. 2011;108(6):1465-71. doi: 10.1007/s00436-010-1237 2195-1.
- 1238 69. Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM, Perkins DJ, Zhou G,
- Githeko A, Yan G. Marked variation in MSP-1 19antibody responses to malaria in western Kenyan highlands.
- 1240 BMC Infect Dis. 2012;12. doi: 10.1186/1471-2334-12-50.
- 1241 70. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, Foy BD. Ivermectin to
- reduce malaria transmission: A research agenda for a promising new tool for elimination. Malar J. 2013;12(1).
- 1243 doi: 10.1186/1475-2875-12-153.
- 1244 71. Coulibaly D, Travassos MA, Tolo Y, Laurens MB, Kone AK, Traore K, Sissoko M, Niangaly A, Diarra
- 1245 I, Daou M, Guindo B, Rebaudet S, Kouriba B, Dessay N, Piarroux R, Plowe CV, Doumbo OK, Thera MA, Gaudart
- 1246 J. Spatio-temporal dynamics of asymptomatic malaria: Bridging the gap between annual Malaria resurgences in
- 1247 a Sahelian environment. Am J Trop Med Hyg. 2017;97(6):1761-9. doi: 10.4269/ajtmh.17-0074.
- 1248 72. Dhawan R, Kumar M, Mohanty AK, Dey G, Advani J, Prasad TSK, Kumar A. Mosquito-borne diseases
- and omics: Salivary gland proteome of the female aedes aegypti mosquito. OMICS: J Integrative Biol.
- 1250 2017;21(1):45-54. doi: 10.1089/omi.2016.0160.
- 1251 73. Fontaine A, Pascual A, Diouf I, Bakkali N, Bourdon S, Fusai T, Rogier C, Almeras L. Mosquito salivary
- gland protein preservation in the field for immunological and biochemical analysis. Parasit Vectors. 2011;4:33.
- 1253 doi: 10.1186/1756-3305-4-33.
- 1254 74. Fontaine A, Pascual A, Orlandi-Pradines E, Diouf I, Remoue F, Pages F, Fusai T, Rogier C, Almeras L.
- 1255 Relationship between Exposure to Vector Bites and Antibody Responses to Mosquito Salivary Gland Extracts.
- 1256 PLoS One. 2011;6(12). doi: 10.1371/journal.pone.0029107. PubMed PMID: WOS:000298369100156.
- 1257 75. Jeon SH, Park JW, Lee BH. Characterization of human IgE and mouse IgG1 responses to allergens in
- three mosquito species by immunoblotting and ELISA. Int Arch Allergy Immunol. 2001;126(3):206-12. doi:
- 1259 10.1159/000049515.

- 1260 Kelly-Hope LA, McKenzie FE. The multiplicity of malaria transmission: A review of entomological
- 1261 inoculation rate measurements and methods across sub-Saharan Africa. Malar J. 2009;8(1). doi: 10.1186/1475-1262 2875-8-19.
- 1263 Kusi KA, Bosomprah S, Dodoo D, Kyei-Baafour E, Dickson EK, Mensah D, Angov E, Dutta S, Sedegah 77.
- 1264 M, Koram KA. Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation.
- 1265 Malar J. 2014;13(1). doi: 10.1186/1475-2875-13-103.
- 1266 Li B, Calvo E, Marinotti O, James AA, Paskewitz SM. Characterization of the c-type lysozyme gene 1267 family in Anopheles gambiae. Gene. 2005;360(2):131-9. doi: 10.1016/j.gene.2005.07.001.
- 1268 Londono-Renteria B, Patel JC, Vaughn M, Funkhauser S, Ponnusamy L, Grippin C, Jameson SB,
- 1269 Apperson C, Mores CN, Wesson DM, Colpitts TM, Meshnick SR. Long-lasting permethrin-impregnated clothing
- 1270 protects against mosquito bites in outdoor workers. Am J Trop Med Hyg. 2015;93(4):869-74. doi:
- 1271 10.4269/ajtmh.15-0130.
- 1272 Mwanziva C, Manjurano A, Mbugi E, Mweya C, Mkali H, Kivuyo MP, Sanga A, Ndaro A, Chambo W,
- 1273 Mkwizu A, Kitau J, Kavishe R, Dolmans W, Chilongola J, Mosha FW. Defining malaria burden from morbidity
- 1274 and mortality records, self treatment practices and serological data in Magugu, Babati district, northern Tanzania.
- 1275 Tanzan J Health Res. 2011;13(2). doi: 10.4314/thrb.v13i2.62980.
- 1276 Sarr J, Orlandi-Pradines E, Fortin S, Sow C, Cornelie S, Rogerie F, Guindo S, Konate L, Fusa T, Riveau
- 1277 G, Rogier C, Remoue F. Assessment of exposure to Plasmodium falciparum transmission in a low endemicity
- 1278 area by using multiplex fluorescent microsphere-based serological assays. Parasit Vectors. 2011;4(1). doi:
- 1279 10.1186/1756-3305-4-212.
- 1280 Satoguina J, Walther B, Drakeley C, Nwakanma D, Oriero EC, Correa S, Corran P, Conway DJ, Walther
- 1281 M. Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in the 1282 Gambia and Guinea Bissau. Malar J. 2009;8(1). doi: 10.1186/1475-2875-8-274.
- 1283 Smithuis FM, Kyaw MK, Phe UO, Van Der Broek I, Katterman N, Rogers C, Almeida P, Kager PA,
- 1284 Stepniewska K, Lubell Y, Simpson JA, White NJ. Entomological determinants of insecticide-treated bed net 1285 effectiveness in Western Myanmar. Malar J. 2013;12(1). doi: 10.1186/1475-2875-12-364.
- 1286 Ubillos I, Campo JJ, Jiménez A, Dobaño C. Development of a high-throughput flexible quantitative
- 1287 suspension array assay for IgG against multiple Plasmodium falciparum antigens. Malar J. 2018;17(1). doi:
- 1288 10.1186/s12936-018-2365-7.
- 1289 85. van den Hoogen LL, Présumé J, Romilus I, Mondélus G, Elismé T, Sepúlveda N, Stresman G, Druetz T,
- 1290 Ashton RA, Joseph V, Eisele TP, Hamre KES, Chang MA, Lemoine JF, Tetteh KKA, Boncy J, Existe A, Drakeley
- 1291 C, Rogier E. Quality control of multiplex antibody detection in samples from large-scale surveys: the example of 1292 malaria in Haiti. Sci Rep. 2020;10(1). doi: 10.1038/s41598-020-57876-0.
- 1293 Varela ML, Koffi D, White M, Niang M, Mbengue B, Diene Sarr F, Touré AO, Perraut R. Practical 1294 example of multiple antibody screening for evaluation of malaria control strategies, Malar J. 2020;19(1), doi:
- 1295 10.1186/s12936-020-03186-9.
- 1296 Wanjala CL, Kweka EJ. Impact of highland topography changes on exposure to malaria vectors and
- 1297 immunity in Western Kenya. Front Public Health. 2016;4(OCT). doi: 10.3389/FPUBH.2016.00227.
- 1298 Armiyanti Y, Arifianto RP, Riana EN, Senjarini K, Widodo W, Fitri LE, Sardjono TW. Identification of 1299 antigenic proteins from salivary glands of female Anopheles maculatus by proteomic analysis. Asian Pac J Trop
- 1300 Biomed. 2016;6(11):924-30. doi: 10.1016/j.apjtb.2016.08.012.
- 1301 Brummer-Korvenkontio H, Palosuo T, François G, Reunala T. Characterization of Aedes communis,
- 1302 Aedes aegypti and Anopheles stephensi mosquito saliva antigens by immunoblotting. Int Arch Allergy Immunol.
- 1303 1997;112(2):169-74. doi: 10.1159/000237450.
- 1304 Cornelie S, Remoue F, Doucoure S, Ndiaye T, Sauvage FX, Boulanger D, Simondon F. An insight into
- 1305 immunogenic salivary proteins of Anopheles gambiae in African children. Malar J. 2007;6:75. doi: 10.1186/1475-1306 2875-6-75.
- 1307 91. Fontaine A, Fusaï T, Briolant S, Buffet S, Villard C, Baudelet E, Pophillat M, Granjeaud S, Rogier C, 1308 Almeras L. Anopheles salivary gland proteomes from major malaria vectors. BMC Genomics. 2012;13:614. doi:
- 1309 10.1186/1471-2164-13-614.
- 1310 Marie A, Holzmuller P, Tchioffo MT, Rossignol M, Demettre E, Seveno M, Corbel V, Awono-Ambéné 92.
- 1311 P, Morlais I, Remoue F, Cornelie S. Anopheles gambiae salivary protein expression modulated by wild
- 1312 Plasmodium falciparum infection: highlighting of new antigenic peptides as candidates of An. gambiae bites.
- 1313 Parasit Vectors. 2014;7:599. doi: 10.1186/s13071-014-0599-y.
- 1314 Owhashi M, Harada M, Suguri S, Omae H, Ishii A. Identification of an eosinophil chemotactic factor
- 1315 from anopheline mosquitoes as a chitinase family protein. Parasitol Res. 2008;102(3):357-63. doi:
- 1316 10.1007/s00436-007-0769-3.

- 1317 94. Penneys NS, Nayar JK, Bernstein H, Knight JW, Leonardi C. Mosquito Salivary Gland Antigens
- 1318 Identified by Circulating Human Antibodies. Arch Dermatol. 1989;125(2):219-22. doi
- 1319 10.1001/archderm.1989.01670140071012.
- 1320 95. Sor-suwan S, Jariyapan N, Roytrakul S, Paemanee A, Phumee A, Phattanawiboon B, Intakhan N,
- 1321 Chanmol W, Bates PA, Saeung A, Choochote W. Identification of salivary gland proteins depleted after blood
- feeding in the malaria vector Anopheles campestris-like mosquitoes (Diptera: Culicidae). PLoS One.
- 1323 2014;9(3):e90809. doi: 10.1371/journal.pone.0090809.
- 1324 96. Sor-Suwan S, Jariyapan N, Roytrakul S, Paemanee A, Saeung A, Thongsahuan S, Phattanawiboon B,
- Bates PA, Poovorawan Y, Choochote W. Salivary gland proteome of the human malaria vector, Anopheles
- 1326 campestris-like (Diptera: Culicidae). Parasitol Res. 2013;112(3):1065-75. doi: 10.1007/s00436-012-3233-y.
- 1327 97. Peng ZK, Li HB, Simons FER. Immunoblot analysis of salivary allergens in 10 mosquito species with
- worldwide distribution and the human IgE responses as these allergens. J Allergy Clin Immunol. 1998;101(4):498-
- 1329 505. doi: 10.1016/s0091-6749(98)70357-4. PubMed PMID: WOS:000073113500012.
- 1330 98. Cornelie S, Senglat M, Doucoure S, Demettre E, Remoue F. Characterization of immunogenic proteins
- in *Anopheles gambiae* salivary glands and their potential use as a marker of exposure to malaria. Am J Trop Med
- 1332 Hyg. 2008;79(6):320-. PubMed PMID: WOS:000261644601456.
- 1333 99. Drame PM, Poinsignon A, Besnard P, Cornelie S, Foumane V, Sow CS, Le Mire J, Fortes F, Boulanger
- D, Carnevale P, Simondon F, Remoue F. Human antibody response to *Anopheles gambiae* saliva: A new immuno-
- epidemiological marker to evaluate the effectiveness of insecticides treated nets (ITNs)? Am J Trop Med Hyg.
- 1336 2008;79(6):358-. PubMed PMID: WOS:000261644601582.
- 1337 100. Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Fortes F, Toto JC, Sembene M, Simondon
- F, Carnevale P, Remoue F. Human antibody response to Anopheles salivary gSG6-P1 peptide: New immuno-
- epidemiological tool for evaluating the efficacy of insecticides treated nets (ITNs) in malaria vector control. Am
- 1340 J Trop Med Hyg. 2010;83(5):260-. PubMed PMID: WOS:000295819701240.
- 1341 101. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B,
- Sokhna C, Arca B, Simondon F, Remoue F. Human IgG response to *Anopheles gambiae* salivary proteins as an
- immuno-epidemiological marker of exposure to malaria vector bites. Am J Trop Med Hyg. 2008;79(6):218-.
- 1344 PubMed PMID: WOS:000261644601102.
- 1345 102. Poinsignon A, Drame PM, Marie A, Noukpo H, Cornelie S, Remoue F. Development of a biomarker of
- exposure to *Anopheles* bites based on human antibody response to salivary proteins: From concept to application
- 1347 in the field. Pathog Glob Health. 2013;107(8):455-. PubMed PMID: WOS:000335056200147.
- 1348 103. Poinsignon A, Drame PM, Samb B, Cornelie S, Sow C, Dia I, Riveau G, Konate L, Sokhna C, Remoue
- 1349 FJ. Development of a new biomarker of exposure to Anopheles bites based on human antibody responses to
- salivary proteins: From the concept to the applications. Am J Trop Med Hyg. 2010;83(5):184-. PubMed PMID:
- 1351 WOS:000295819700617.
- 1352 104. Sagna AB, Kassie D, Couvray A, Hermann E, Riveau G, Salem G, Fournet F, Remoue F. Spatial risk of
- 1353 urban exposure to Anopheles and Aedes mosquito bites in africa using salivary antibody-based biomarkers. Am J
- 1354 Trop Med Hyg. 2018;99(4):47-. PubMed PMID: WOS:000461386602150.
- 1355 105. Dragovic SM, Agunbiade TA, Freudzon M, Yang J, Hastings AK, Schleicher TR, Zhou X, Craft S,
- 1356 Chuang YM, Gonzalez F, Li Y, Hrebikova G, Tripathi A, Mlambo G, Almeras L, Ploss A, Dimopoulos G, Fikrig
- E. Immunization with AgTRIO, a Protein in Anopheles Saliva, Contributes to Protection against Plasmodium
- 1358 Infection in Mice. Cell Host Microbe. 2018;23(4):523-35.e5. doi: 10.1016/j.chom.2018.03.008.
- 1359 106. King JG, Vernicks KD, Hillyer JF. Members of the salivary gland surface protein (SGS) family are major
- immunogenic components of mosquito saliva. J Biol Chem. 2011;286(47):40824-34. doi:
- 1361 10.1074/jbc.M111.280552.
- 1362 107. Vogt MB, Lahon A, Arya RP, Kneubehl AR, Spencer Clinton JL, Paust S, Rico-Hesse R. Mosquito
- saliva alone has profound effects on the human immune system. PLoS Negl Trop Dis. 2018;12(5). doi:
- 1364 10.1371/journal.pntd.0006439.
- 1365 108. Wang J, Zhang Y, Zhao YO, Li MW, Zhang L, Dragovic S, Abraham NM, Fikrig E. Anopheles gambiae
- circumsporozoite protein-binding protein facilitates plasmodium infection of mosquito salivary glands. J Infect
- 1367 Dis. 2013;208(7):1161-9. doi: 10.1093/infdis/jit284.
- 1368 109. Almeida AP, Billingsley PF. Induced immunity against the mosquito Anopheles stephensi: reactivity
- 1369 characteristics of immune sera. Med Vet Entomol. 1999;13(1):53-64. doi: 10.1046/j.1365-2915.1999.00143.x.
- 1370 110. Boulanger D, Doucoure S, Grout L, Ngom A, Rogerie F, Cornelie S, Sokhna C, Mouchet F, Riveau G,
- 1371 Simondon F, Remoue FJ. Immunoglobulin G antibody profiles against Anopheles salivary proteins in domestic
- animals in Senegal. J Med Entomol. 2011;48(3):691-3. doi: 10.1603/me10183.
- 1373 111. Kerkhof K, Canier L, Kim S, Heng S, Sochantha T, Sovannaroth S, Vigan-Womas I, Coosemans M,
- Sluydts V, Ménard D, Durnez L. Implementation and application of a multiplex assay to detect malaria-specific

- 1375 antibodies: a promising tool for assessing malaria transmission in Southeast Asian pre-elimination areas. Malar J.
- 1376 2015;14:338. doi: 10.1186/s12936-015-0868-z.
- 1377 Sagna AB, Gaayeb L, Sarr JB, Senghor S, Poinsignon A, Boutouaba-Combe S, Schacht AM, Hermann
- 1378 E, Faye N, Remoue F, Riveau G. Plasmodium falciparum infection during dry season: IgG responses to Anopheles
- 1379 gambiae salivary gSG6-P1 peptide as sensitive biomarker for malaria risk in Northern Senegal. Malar J. 1380 2013;12:301. doi: 10.1186/1475-2875-12-301.
- 1381 113. Ya-Umphan P, Cerqueira D, Cottrell G, Parker DM, Fowkes FJI, Nosten F, Corbel V. Anopheles salivary
- 1382 biomarker as a proxy for estimating *Plasmodium falciparum* malaria exposure on the Thailand-Myanmar Border.
- 1383 Am J Trop Med Hyg. 2018;99(2):350-6.
- 1384 Aka KG, Traoré DF, Sagna AB, Zoh DD, Assi SB, Tchiekoi BN, Adja AM, Remoue F, Poinsignon A.
- 1385 Pattern of antibody responses to Plasmodium falciparum antigens in individuals differentially exposed to
- 1386 Anopheles bites. Malar J. 2020;19(1):83. doi: 10.1186/s12936-020-03160-5.
- 1387 Drame PM, Diallo A, Poinsignon A, Boussari O, Dos Santos S, Machault V, Lalou R, Cornelie S,
- 1388 LeHesran JY, Remoue F. Evaluation of the effectiveness of malaria vector control measures in urban settings of
- 1389 **PLoS** Dakar specific Anopheles salivary biomarker. One. 2013;8(6):e66354. 1390
- 10.1371/journal.pone.0066354.
 - 1391 Londono-Renteria BL, Eisele TP, Keating J, James MA, Wesson DM. Antibody response against
 - 1392 Anopheles albimanus (Diptera: Culicidae) salivary protein as a measure of mosquito bite exposure in Haiti. J Med
 - 1393 Entomol. 2010;47(6):1156-63. doi: 10.1603/me09240.
 - 1394 Noukpo MH, Damien GB, Elanga-N'Dille E, Sagna AB, Drame PM, Chaffa E, Boussari O, Corbel V, 117.
 - 1395 Akogbéto M, Remoue F. Operational assessment of long-lasting insecticidal nets by using an Anopheles salivary
 - 1396 biomarker of human-vector contact. Am J Trop Med Hyg. 2016;95(6):1376-82. doi: 10.4269/ajtmh.15-0541.
 - 1397 Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A,
 - 1398 Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, 1399 Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-
 - 1400 based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020;395(10242):1998-
 - 1401 2007. doi: 10.1016/S0140-6736(20)31048-5. PubMed PMID: ClinicalTrials.gov/NCT03055000.
 - 1402 119. Mendes-Sousa AF, Vale VF, Queiroz DC, Pereira-Filho AA, da Silva NCS, Koerich LB, Moreira LA,
 - 1403 Pereira MH, Sant'Anna MR, Araújo RN, Andersen J, Valenzuela JG, Gontijo NF. Inhibition of the complement
 - 1404 system by saliva of Anopheles (Nyssorhynchus) aquasalis. Insect Biochem Mol Biol. 2018;92:12-20. doi:
 - 1405 10.1016/j.ibmb.2017.11.004.
 - 1406 120. Peng Z, Beckett AN, Engler RJ, Hoffman DR, Ott NL, Simons FE. Immune responses to mosquito saliva
 - 1407 in 14 individuals with acute systemic allergic reactions to mosquito bites. J Allergy Clin Immunol. 1408 2004;114(5):1189-94. doi: 10.1016/j.jaci.2004.08.014.

 - 1409 Londono-Renteria B, Cardenas JC, Troupin A, Colpitts TM. Natural mosquito-pathogen hybrid IgG4
 - 1410 antibodies vector-borne diseases: Α hypothesis. Front Immunol. 2016;7(SEP).
 - 1411 10.3389/fimmu.2016.00380.
 - 1412 Owhashi M, Harada M, Suguri S, Ohmae H, Ishii A. The role of saliva of Anopheles stephensi in
 - 1413 inflammatory response: identification of a high molecular weight neutrophil chemotactic factor. Parasitol Res.
 - 1414 2001;87(5):376-82. doi: 10.1007/s004360000355.
 - 1415 Armiyanti Y, Nuryady MM, Arifianto RP, Nurmariana E, Senjarini K, Fitri LE, Sardjono TW. Detection
 - 1416 of immunogenic proteins from Anopheles sundaicus salivary glands. Revista da Sociedade Brasileira de Medicina
 - 1417 Tropical. 2015;48(4):410-6. doi: 10.1590/0037-8682-0185-2015.
 - 1418 Opasawatchai A, Yolwong W, Thuncharoen W, Inrueangsri N, Itsaradisaikul S, Sasisakulporn C,
 - 1419 Jotikasthira W, Matangkasombut O, Reamtong O, Manuyakorn W, Songnuan W, Matangkasombut P. Novel
 - 1420 salivary gland allergens from tropical mosquito species and IgE reactivity in allergic patients. World Allergy
 - 1421 Organ J. 2020;13(2). doi: 10.1016/j.waojou.2020.100099.
 - 1422 Orlandi-Pradines E, Almeras L, Denis de Senneville L, Barbe S, Remoué F, Villard C, Cornelie S,
 - 1423 Penhoat K, Pascual A, Bourgouin C, Fontenille D, Bonnet J, Corre-Catelin N, Reiter P, Pagés F, Laffite D,
- 1424 Boulanger D, Simondon F, Pradines B, Fusaï T, Rogier C. Antibody response against saliva antigens of Anopheles
- 1425 gambiae and Aedes aegypti in travellers in tropical Africa. Microbes Infect. 2007;9(12-13):1454-62. doi:
- 1426 10.1016/j.micinf.2007.07.012.
- 1427 Ambrosino E, Dumoulin C, Orlandi-Pradines E, Remoue F, Toure-Baldé A, Tall A, Sarr JB, Poinsignon
- 1428 A, Sokhna C, Puget K, Trape JF, Pascual A, Druilhe P, Fusai T, Rogier C. A multiplex assay for the simultaneous
- 1429 detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens. Malar J.
- 1430 2010;9:317. doi: 10.1186/1475-2875-9-317.

- 1431 127. Kerkhof K, Sluydts V, Willen L, Kim S, Canier L, Heng S, Tsuboi T, Sochantha T, Sovannaroth S,
- 1432 Ménard D, Coosemans M, Durnez L. Serological markers to measure recent changes in malaria at population
- 1433 level in Cambodia. Malar J. 2016;15(1):1-18. doi: 10.1186/s12936-016-1576-z.
- 1434 128. Koffi D, Touré AO, Varela ML, Vigan-Womas I, Béourou S, Brou S, Ehouman MF, Gnamien L, Richard
- 1435 V, Djaman JA, Perraut R. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory
- 1436 Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIXTM). Malar J.
- 1437 2015;14:509. doi: 10.1186/s12936-015-1043-2.
- 1438 129. Koffi D, Varela ML, Loucoubar C, Beourou S, Vigan-Womas I, Touré A, Djaman JA, Touré AO, Perraut
- R. Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission
- in peri-urban area of Cote d'Ivoire between 2010 and 2013. PLoS One. 2017;12(2):e0172899. doi:
- 1441 10.1371/journal.pone.0172899.
- 1442 130. Perraut R, Varela ML, Loucoubar C, Niass O, Sidibé A, Tall A, Trape JF, Wotodjo AN, Mbengue B,
- 1443 Sokhna C, Vigan-Womas I, Touré A, Richard V, Mercereau-Puijalon O. Serological signatures of declining
- exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One.
- 1445 2017;12(6):e0179146. doi: 10.1371/journal.pone.0179146.
- 1446 131. Proietti C, Verra F, Bretscher MT, Stone W, Kanoi BN, Balikagala B, Egwang TG, Corran P, Ronca R,
- 1447 Arcà B, Riley EM, Crisanti A, Drakeley C, Bousema T. Influence of infection on malaria-specific antibody
- dynamics in a cohort exposed to intense malaria transmission in northern Uganda. Parasite Immunol. 2013;35(5-
- 1449 6):164-73. doi: 10.1111/pim.12031.
- 1450 132. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander
- T, Ronca R, Modiano D, Arcà B, Drakeley C. IgG responses to *Anopheles gambiae* salivary antigen gSG6 detect
- 1452 variation in exposure to malaria vectors and disease risk. PLoS One. 2012;7(6):e40170. doi:
- 1453 10.1371/journal.pone.0040170.
- 1454 133. Ya-Umphan P, Cerqueira D, Parker DM, Cottrell G, Poinsignon A, Remoue F, Brengues C,
- 1455 Chareonviriyaphap T, Nosten F, Corbel V. Use of an *Anopheles* salivary biomarker to assess malaria transmission 1456 risk along the Thailand-Myanmar Border. J Infect Dis. 2017;215(3):396-404. doi: 10.1093/infdis/jiw543.
- 1457 134. Idris ZM, Chan CW, Mohammed M, Kalkoa M, Taleo G, Junker K, Arcà B, Drakeley C, Kaneko A.
- Serological measures to assess the efficacy of malaria control programme on Ambae Island, Vanuatu. Parasit
- 1459 Vectors. 2017;10(1):204. doi: 10.1186/s13071-017-2139-z.
- 1460 135. Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M, Bostrom S, Ronca R, Rooth I,
- Farnert A. Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.
- 1462 Sci Rep. 2016;6. doi: 10.1038/srep19472. PubMed PMID: WOS:000369380100001.
- 1463 136. Badu K, Gyan B, Appawu M, Mensah D, Dodoo D, Yan G, Drakeley C, Zhou G, Owusu-Dabo E, Koram
- 1464 KA. Serological evidence of vector and parasite exposure in Southern Ghana: the dynamics of malaria
- transmission intensity. Parasit Vectors. 2015;8:251. doi: 10.1186/s13071-015-0861-y.
- 1466 137. Sarr JB, Samb B, Sagna AB, Fortin S, Doucoure S, Sow C, Senghor S, Gaayeb L, Guindo S, Schacht
- 1467 AM, Rogerie F, Hermann E, Dia I, Konate L, Riveau G, Remoue F. Differential acquisition of human antibody
- 1468 responses to *Plasmodium falciparum* according to intensity of exposure to *Anopheles* bites. Trans R Soc Trop
- 1469 Med Hyg. 2012;106(8):460-7. doi: 10.1016/j.trstmh.2012.05.006.
- 1470 138. Drame PM, Poinsignon A, Dechavanne C, Cottrell G, Farce M, Ladekpo R, Massougbodji A, Cornélie
- 1471 S, Courtin D, Migot-Nabias F, Garcia A, Remoué F. Specific antibodies to Anopheles gSG6-P1 salivary peptide
- to assess early childhood exposure to malaria vector bites. Malar J. 2015;14:285. doi: 10.1186/s12936-015-0800-6.
- 1474 139. Ali ZM, Bakli M, Fontaine A, Bakkali N, Vu Hai V, Audebert S, Boublik Y, Pagès F, Remoué F, Rogier
- 1475 C, Fraisier C, Almeras L. Assessment of Anopheles salivary antigens as individual exposure biomarkers to
- 1476 species-specific malaria vector bites. Malar J. 2012;11:439. doi: 10.1186/1475-2875-11-439.
- 1477 140. Rizzo C, Ronca R, Fiorentino G, Mangano VD, Sirima SB, Nèbiè I, Petrarca V, Modiano D, Arcà B.
- Wide cross-reactivity between Anopheles gambiae and Anopheles funestus SG6 salivary proteins supports
- exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa. Malar J.
- 1480 2011;10:206. doi: 10.1186/1475-2875-10-206.
- 1481 141. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M, Boulanger D, Cisse B,
- 1482 Sokhna C, Arcà B, Simondon F, Remoue F. Novel peptide marker corresponding to salivary protein gSG6
- 1483 potentially identifies exposure to Anopheles bites. PLoS One. 2008;3(6):e2472. doi:
- 1484 10.1371/journal.pone.0002472.
- 1485 142. Rizzo C, Lombardo F, Ronca R, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Modiano D, Arcà B.
- Differential antibody response to the *Anopheles gambiae* gSG6 and cE5 salivary proteins in individuals naturally
- 1487 exposed to bites of malaria vectors. Parasit Vectors. 2014;7:549. doi: 10.1186/s13071-014-0549-8.

- 1488 143. Drame PM, Poinsignon A, Besnard P, Le Mire J, Dos-Santos MA, Sow CS, Cornelie S, Foumane V,
- 1489 Toto JC, Sembene M, Boulanger D, Simondon F, Fortes F, Carnevale P, Remoue F. Human antibody response to
- 1490 Anopheles gambiae saliva: an immuno-epidemiological biomarker to evaluate the efficacy of insecticide-treated
- 1491 nets in malaria vector control. Am J Trop Med Hyg. 2010;83(1):115-21. doi: 10.4269/ajtmh.2010.09-0684.
- 1492 Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F. Evaluation of the antibody
- 1493 response to Anopheles salivary antigens as a potential marker of risk of malaria. Trans R Soc Trop Med Hyg.
- 1494 2006;100(4):363-70. doi: 10.1016/j.trstmh.2005.06.032.
- 1495 Lawaly R, Konate L, Marrama L, Dia I, Diallo D, Sarr FD, Schneider BS, Casademont I, Diallo M, Brey
- 1496 PT, Sakuntabhai A, Mecheri S, Paul R. Impact of mosquito bites on asexual parasite density and gametocyte
- 1497 prevalence in asymptomatic chronic Plasmodium falciparum infections and correlation with IgE and IgG titers.
- 1498 Infect Immun. 2012;80(6):2240-6. doi: 10.1128/iai.06414-11. PubMed PMID: WOS:000304387700031.
- 1499 Rizzo C, Ronca R, Lombardo F, Mangano V, Sirima SB, Nèbiè I, Fiorentino G, Troye-Blomberg M,
- 1500 Modiano D, Arcà B. IgG1 and IgG4 antibody responses to the *Anopheles gambiae* salivary protein gSG6 in the
- 1501 sympatric ethnic groups Mossi and Fulani in a malaria hyperhendemic area of Burkina Faso. PLoS One.
- 1502 2014:9(4):e96130. doi: 10.1371/journal.pone.0096130.
- 1503 Marie A, Ronca R, Poinsignon A, Lombardo F, Drame PM, Cornelie S, Besnard P, Le Mire J, Fiorentino
- 1504 G, Fortes F, Carnevale P, Remoue F, Arcà B. The Anopheles gambiae cE5 salivary protein: a sensitive biomarker
- 1505 to evaluate the efficacy of insecticide-treated nets in malaria vector control. Microbes Infect. 2015;17(6):409-16.
- 1506 doi: 10.1016/j.micinf.2015.01.002.
- 1507 Brosseau L, Drame PM, Besnard P, Toto JC, Foumane V, Le Mire J, Mouchet F, Remoue F, Allan R, 148.
- 1508 Fortes F, Carnevale P, Manguin S. Human antibody response to Anopheles saliva for comparing the efficacy of
- 1509 three malaria vector control methods in Balombo, Angola. PLoS One. 2012;7(9):e44189. doi: 1510 10.1371/journal.pone.0044189.
- 1511 149. Londono-Renteria B, Drame PM, Montiel J, Vasquez AM, Tobón-Castaño A, Taylor M, Vizcaino L,
- 1512 Lenhart AAE. Identification and pilot evaluation of salivary peptides from Anopheles albimanus as biomarkers
- 1513 for bite exposure and malaria infection in Colombia. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21030691.
- 1514 Andrade BB, Rocha BC, Reis-Filho A, Camargo LM, Tadei WP, Moreira LA, Barral A, Barral-Netto
- 1515 M. Anti-Anopheles darlingi saliva antibodies as marker of Plasmodium vivax infection and clinical immunity in
- 1516 the Brazilian Amazon. Malar J. 2009;8:121. doi: 10.1186/1475-2875-8-121.
- 1517 Waitayakul A, Somsri S, Sattabongkot J, Looareesuwan S, Cui L, Udomsangpetch R. Natural human 151.
- 1518 humoral response to salivary gland proteins of Anopheles mosquitoes in Thailand. Acta Trop. 2006;98(1):66-73.
- 1519 doi: 10.1016/j.actatropica.2006.02.004.
- 1520 Montiel J, Carbal LF, Tobón-Castaño A, Vásquez GM, Fisher ML, Londono-Rentería B. IgG antibody
- 1521 response against Anopheles salivary gland proteins in asymptomatic Plasmodium infections in Narino, Colombia.
- 1522 Malar J. 2020;19(1):42. doi: 10.1186/s12936-020-3128-9.